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Many children under the age of 5 die each year of invasive pneumococcal disease. 
Childhood vaccination against this disease reduces morbidity and mortality. Despite the 
introduction of a pneumococcal conjugate vaccine (PCV13) in a central African country 
in 2011, all provinces have not yet been vaccinated. The purpose of this quantitative 
quasi-experimental study was to determine whether there was an association between the 
introduction of PCV13 and new cases of pneumococcal disease in 2 provinces in central 
Africa. The sample size for the study was 380. The theoretical framework for this study 
was the epidemic model supported by the concept of herd immunity. Key research 
questions examined the incidence of pneumococcal disease in children by age, gender, 
and province. The independent variables were age, gender, province, and introduction of 
PCV13. The dependent variable was incidence of invasive pneumococcal disease. The 
research questions were evaluated using chi-square test of independence and logistic 
regression. The results of the study indicated that vaccination with PCV13 significantly 
reduced incident cases of invasive pneumococcal diseases (aOR 0.333, 95% CI 0.628-
0.177, p = 0.001). However, this association was not significant for age (aOR 0.574, 95% 
CI 1.186-0.278, p = .134), and there were no significant gender differences (aOR 1.047, 
95% CI 1.929-0.569, p = 0.882). Positive social change may result by enabling the 
protection of more children in the central Africa country provinces that have not yet 
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Chapter 1:  Introduction to the Study 
Introduction 
 The gram-positive bacterium that causes invasive pneumococcal infections (such 
as pneumonia, septicemia, and meningitis) especially in children is the streptococcus 
pneumoniae (S. Pneum) or streptococcus; this bacterium is a normal inhabitant of the 
upper respiratory track flora (Grall et al., 2011). According to the Centers for Disease 
Control and Prevention (CDC, 2011), in 2008, about 1.6 million children less than 5 
years of age die because of pneumococcal diseases worldwide each year, and over 95 % 
of them of these deaths occur in the developing world. This shows that the disease is a 
public health concern for younger children with a higher burden for the under developed 
world.  
 Pneumococcal infection starts with the bacteria colonizing in the nasopharynx of 
healthy children, where it grows and establishes a carriage. At this stage, the 
pneumococcus can either remain asymptomatic or can take three different paths: 
potentially causing otitis media (ear ache) by migrating through the eustachian tube, 
pneumonia by descending down the respiratory tract, or meningitis by invading the 
bloodstream through the respiratory epithelium (Dube, Kaba, Whittaker, Zar, & Nicol, 
2013). Forty six serogroups and at least 93 serotypes of streptococcus pneumoniae have 
been identified (Coskun-Ari1, Guldemir, & Durmaz, 2012). So far, only a small number 
of the 93 serotypes have been detected from patients with invasive pneumococcal disease 
worldwide; that number was distributed according to age, sex, and geography (Dashti, 
Abdinia, & Karimi, 2012). Pneumococcal infection is treated with antibiotics, but more 





on the prevention of the disease in order to reduce morbidity and mortality (Liňares, 
Ardanuy, Pallares, & Fenol, 2010).   
 The most cost effective prevention of pneumococcal disease in children is through 
vaccination with pneumococcal conjugate vaccine (PCV) (Pittet, & Posfay-Barbe, 2012). 
The protection is achieved by the induction of a protective antibody response against the 
bacterial polysaccharide capsule. PCV vaccine available to date only includes antibodies 
against 13 out of the 93 serotypes (Weil-Olivier, van der Linden, de Schutter, Dagan, and 
Mantovani, 2012). Three different vaccines have been developed; starting with the seven 
valents (PCV7) containing the seven most diseases causing serotypes that are 4, 6B, 9V, 
14, 18C, 19F, and 23F; followed by the 10 valents (PCV10) containing three additional 
serotypes (1, 5, 7F), and the PCV 13 containing six additional serotypes 1, 3, 5, 6A, 7F, 
and 19A (Weil-Olivier et al., 2012). Even though PCV 7 has reduced the incidence of the 
disease, pneumococcal disease was caused by the non vaccine serotype in some cases 
(Weil-Olivier et al., 2012); therefore, a vaccine covering more serotypes was needed, 
resulting in the development of PCV10 and PCV13.   
 According to the Democratic Republic of Congo (DRC’s) Ministry of health, 
beginning in April 2011, the vaccine began to be introduced in DRC by province to 
eventually cover the entire country. Therefore, it is important to study the impact of the 
vaccine in the reduction of the burden of the disease in order to cover the entire country 
in DRC and/or other African countries. The PCV13 shields 13 serotypes, which is highly 
effective; however, more research is needed for the development of vaccines with greater 
coverage in the future. To achieve this, it will be crucial to monitor the circulating 





available in that setting, and then compare the circulating strains and the ones included in 
the vaccine (Sakai, Talekar, Klugman, & Vidal, 2013). An effective vaccine has the 
potential to eliminate many sick children and unnecessary deaths due to pneumococcal 
infections. 
 The chapter begins with the background of the problem, problem statement, and 
significance of the study. The chapter includes the research questions that guided the 
study, as well as a short definition of main terms. The theoretical framework for the study 
is also presented, with further discussion provided in the literature review. In these 
sections, I establish the goals for the study and illustrate the need for continued 
pneumococcal vaccine research in the field of health. 
Background of the Study 
 Pneumococcal disease is caused by infection with streptococcus pneumoniae 
bacteria. These bacteria can spread from one person to another person through close 
contact (CDC, 2013). Pneumococcal disease can lead to severe health problems, 
including pneumonia, blood infections, and meningitis (CDC, 2013). Pneumococcal 
infection is generally preceded by a colonization of germs in the nasopharynx, which is 
usually asymptomatic (without symptoms) in most of the cases and does not turn into the 
disease (Dube et al., 2013). When the colonization transitions to the disease phase, it can 
be severe, affecting a child’s quality of life, and sometimes death occurs (Rodewald, 
Maes, Stevenson, Lyons, Stokley, & Szilagyi, 1999). The asymptomatic carrier state is 
mostly seen in children attending daycare centers; therefore, those children constitute the 





 Pneumococcal disease is prevented with available pneumococcal vaccines. As of 
2012, the World Health Organization recommended using pneumococcal vaccines as a 
part of the routine childhood vaccination schedule; 86 countries have introduced the 
vaccine including 23 low-income member states. The 23 low-income countries had the 
assistance of the Global Alliance for Vaccines and Immunizations (GAVI) to finance the 
vaccine (WHO, 2012). The burden of pneumococcal disease caused by streptococcus 
pneumoniae in sub-Saharan Africa has prompted the GAVI Alliance to finance the 
introduction of the vaccine in several countries including the DRC (WHO, 2012). 
According to the WHO (2013), pneumonia was the leading cause of death in the DRC 
since the year 2000 as compared to all other causes of death in children less than 5 years 
of age. Research has been conducted to study the impact of the pneumococcal conjugate 
vaccine on the reduction of invasive pneumococcal diseases in different countries, but no 
studies have been conducted in the DRC. In this study, I address the gap in knowledge of 
the impact of the PCV13 on the circulating strains of streptococcus pneumoniae in the 
DRC. 
Low-income countries face difficulty in affording and sustaining quality 
lifesaving vaccines; therefore, in order for their programs to generate the most desirable 
outcomes from a public health standpoint, alternative solutions need to be put in place. 
Due to the high cost of vaccines and the difficulties in sustainability, manufacturing 
appropriate vaccine products has proven to be difficult due to underinvestment. Peltola, 
Booy, and Schmitt (2004) claimed that the high cost of vaccines keeps many children 
from getting a highly effective vaccine against the pneumococcal diseases. There is a 





the market risks, a pilot initiative called the Advance Market Commitment (AMC) for 
pneumococcal vaccines was launched in 2009 (Cernuschi et al., 2011). These initiatives 
set predetermined terms that legally bind the purchasing of vaccines. To date, 14 
countries have already introduced pneumococcal vaccines through the AMC with 39 
countries expected to introduce before the end of 2013 (Cernuschi et al., 2011). This has 
helped protect more children through routine vaccination therefore reduce the burden of 
the disease. 
Problem Statement 
There is a high incidence of pneumococcal diseases among children worldwide. 
Pneumococcal disease is classified as the leading cause of mortality and morbidity in 
children worldwide (Cohen, Hyde, Verania, & Watkins, 2012). Prevention of the disease 
is important in reducing the morbidity and mortality of the disease and the best, most 
cost-effective prevention is immunization through childhood vaccination (CDC, 2012). 
Antao and Hausdorff, (2009) claimed that there is a high burden of pneumococcal 
diseases in children and stated that the disease can be prevented with an available 
vaccine. The bulk of pneumococcal research has focused on the burden and antibiotic 
treatment, without giving equal attention to the prevention of the disease with the 
available vaccines and the effectiveness of the vaccine. This discrepancy led scholars to 
examine the pneumococcal conjugate vaccine, which may help reduce the morbidity and 
mortality of the invasive form of the disease. 
 Although the vaccine has been shown to have an impact in some African 
countries as well as some South and North American and Europeans countries, there was 





Starting in April 2011, according to the DRC’s Ministry of health, the pneumococcal 
conjugate vaccine (PCV13) began gradually being introduced into the DRC’s expanded 
program of immunization to eventually cover the whole country; thus far, it has reached 
five of the country’s 11 provinces: The first two provinces (Kinshasa and Bas Congo) 
introduced the vaccine in April 2011, followed by two other provinces (Nord Kivu and 
South Kivu) in July 2011 and the province of Bandundu in October 2011. A total of 
677,308 children were targeted in the five provinces, and as of July 2013 the coverage 
with PCV13 was 88.8% as reported by the DRC’s immunization authority. Evaluation of 
the effectiveness of the vaccine was a key step in continuing with the introduction of the 
vaccine to the entire country; therefore, there was a need to evaluate the provinces that 
have immunized thus far. 
Purpose of the Study 
 The purpose of this quantitative secondary data analysis was to determine if a 
relationship existed between two DRC provinces where PCV13 had been introduced/not 
introduced and determine if the covariates (age and gender) had an impact on that 
relationship. The intent of this study was to examine the relationship between DRC 
provinces’ childhood immunization rates for pneumococcal vaccine and the incidence of 
invasive pneumococcal disease. The independent variable was province (Kinshasa, 
Katanga). The dependent variable was the number of incident cases (observed, not 
observed).  
An association between the pneumococcal vaccination rates of children who have 
routinely been vaccinated against the disease and the prevention of the disease might 





vaccine for all young children. Health care personnel in the DRC might be more 
motivated to routinely recommend and use the vaccine if they understand through 
evidentiary data that children’s lives will be improved by eliminating this disease from 
their lives.   
Research Questions and Hypotheses 
RQ1: What is the difference in the number of incident cases of invasive 
pneumococcal disease in children between the Kinshasa province following the 
introduction of PCV13 and a comparison group in the Katanga province where the 
vaccine was not introduced? 
Directional Hypothesis 1:  
H01: There is no difference in the number of incident cases of invasive 
pneumococcal disease in children between the Kinshasa province following the 
introduction of PCV 13 and the Katanga province where the vaccine was not introduced.  
Ha1: Children in Kinshasa province where the PCV 13 was introduced showed a 
decrease in the number of incident cases of invasive pneumococcal disease as compared 
to the children of the same age in the Katanga province where the vaccine was not 
introduced. 
 Dependent variable: Number of incident cases (observed, not observed) 
 Independent variable: province type: (Kinshasa, Katanga) 
 Statistical analysis: Chi-square test of independence 
RQ2: Is there an association between age and incident cases of invasive 
pneumococcal disease in children among the Kinshasa province (PCV13) and Katanga 





Directional Hypothesis 2: 
H02: There is no association between age and incident cases of invasive 
pneumococcal disease in children controlling for province (intervention vs. control) 
Ha2: Older children (2-5 years) were more likely to contract invasive 
pneumococcal disease in the control province compared to the PCV13 intervention 
province 
 Dependent variable: Number of incident cases (observed, not observed) 
 Independent variable: Province type: (Kinshasa, Katanga) 
 Covariate: Age 
 Statistical analysis: Logistic regression 
RQ3: Is there an association between gender and incident cases of invasive 
pneumococcal disease in children among the Kinshasa province (PCV13) and Katanga 
province (control)? 
Directional Hypothesis 3: 
H03: There is no association between gender and incident cases of invasive 
pneumococcal disease in children controlling for province (intervention vs. control) 
Ha3: Males were more likely to contract invasive pneumococcal disease in the 
control province compared to the PCV13 intervention province. 
 Dependent variable: Number of incident cases (observed, not observed) 
 Independent variable: Province type: (Kinshasa, Katanga) 
 Covariate: Gender 





The objective of this study was to determine whether vaccinating young children 
against pneumococcal disease protected one community better than those communities 
that have not yet adopted routine vaccination with pneumococcal vaccine. The 
pneumococcal vaccination of young children has been shown to prevent serious illness, 
hospitalizations, and even death (Rodewald et al., 1999). If vaccination of young children 
against pneumococcal disease had an additional benefit to protect communities, then 
there may be an additional reason to require health care personnel to use the available 
PCV vaccines. 
Theoretical Framework 
The theoretical framework for this study was the epidemic model, supported by 
the concept of herd immunity. An epidemic model is based on the following assumptions: 
(a) infectious disease is transmitted by person-to-person contact only; (b) persons 
susceptible to the disease will develop the disease after contact with an infected person, 
thereby acquiring immunity to the illness; (c) there is a fixed probability of coming in 
contact with an infectious person; (d) the population has no contact with anyone outside 
the community; and (e) the conditions remain constant throughout the epidemic (Fine, 
1977). Herd immunity or threshold protects susceptible individuals in a community from 
disease assuming there is a minimum vaccination threshold (Libster & Edwards, 2011, p. 
163; Piedra et al., 2005). Herd immunity applies to infectious disease that can be 
transmitted from person to person. 
Nature of the Study 
A quantitative, quasi-experimental research design was used to test the 





and age and gender and looking prospectively at who got the disease and who did not. I 
evaluated an intervention site with another site not receiving the intervention. The data 
were collected during routine surveillance of the invasive pneumococcal diseases. A 
quantitative approach was appropriate because the hypotheses derive from the theoretical 
framework. 
The study was guided by three research questions about whether or not there was 
a difference in the number of incident cases of invasive pneumococcal disease between 
the children in Kinshasa province following the introduction of PCV13 and a comparison 
group in the Katanga province where the vaccine was not introduced. The dependent 
variable for H1-H3 was number of incident cases of the disease. The independent 
variables were province type (Kinshasa or Katanga), gender (male, female) and age 
groups.   
Archival data on the entire population that were extracted from the surveillance 
system data were used. Archival data represented the best method because it was not only 
less time consuming than collecting the data on my own, but they were readily available. 
The data were originally collected as part of the normal surveillance system of the DRC 
ministry of health (Frankfort-Nachmias & Nachmias, 2008). Permission was received 
from the government of the DRC for use of the archival data in the study (Appendix B). 
The data were originally collected after administration of a questionnaire (Appendix C) to 
each visiting patient.  
The population for this study was children who lived in the DRC, and who had 
been immunized with PCV13 starting in April 2011 as recorded in an official regional 





group in the Katanga province was used where the vaccine was not introduced. The 
sample was taken from the sentinels surveillance data of pneumococcal disease in the 
municipalities of Kalembelembe, Kingasani of the Kinshasa province and the hospital of 
Sendwe in the Katanga Province in DRC. There were an estimated 67.51 million people 
in the DRC including 3 400 000 children in the year 2012 (WHO, 2013). According to 
the DRC’s immunization authority, as of July 2013, 958 809 (54.4%) children less than 
1-year-old received the first dose of PCV13 against 675977 (38.4%) who received the 
third dose. In 2009 the pneumococcal disease incidence was ≥ 3000 per 100,000 children 
less than 5 years of age; the mortality rate was between 300 and 500 per 100,000 children 
less than 5 years of age (Wang, 2009). In the same year, DRC was among the 10 
countries with the greatest pneumococcal deaths in the world all of which are in Africa 
and Asia (Wang, 2009). 
Definitions 
The following definitions are commonly used in public health to describe 
pneumococcal vaccination as it relates to health care: 
Antibodies: Proteins generally found in the blood that detect and destroy invaders, 
like bacteria and viruses. Part of the immune system, antibodies come in different types, 
called isotypes. Mammals carry five isotypes. Each performs a different role in the body 
(Jewett-Tennant, 2013). 
Bacteria: Any of a large group of single-celled microorganisms that display a 
wide range of metabolic types, geometric shapes, and environmental habitats and niches 
of occurrence. Normally only several micrometers in length, bacteria assume the form of 





Eustachian tube: A passage from the tympanum of the ear to the pharynx 
(Merriam Co, 1913).   
Gram positive Bacteria: A bacterium that retains the violet stain used in Gram's 
method. In gram positive bacteria, about 90% of the cell wall is made up of 
peptidoglycan and small amounts of teichoic acid (Amils, 2011). 
Herd immunity: Herd immunity is a public health prevention strategy to reduce 
ongoing transmission of vaccine-preventable diseases (Plans-Rubió, 2012). When a 
sufficient number of individuals are immune to a disease, the disease cannot continue to 
be transmitted person-to-person (Plans-Rubió, 2012). Herd immunity works to reduce 
risk of infection in the susceptible person by surrounding them with people who are 
immune to the disease. 
Infection: An invasion by and multiplication of pathogenic microorganisms in a 
bodily part or tissue, which may produce subsequent tissue injury and progress to overt 
disease through a variety of cellular or toxic mechanisms (Thomson & Smith, 1994). 
Nasopharynx: The area of the upper throat that lies behind the nose (Moss, 1989) 
Meningitis: According to CDC (2014), meningitis is defined as the inflammation 
of the membranes of the brain or spinal cord.  
Otitis media: An acute or chronic inflammation of the middle ear. An acute 
inflammation, especially in infants or young children, that is caused by a virus or 
bacterium; usually occurs as a complication of an upper respiratory infection; and is 
marked by earache, fever, hearing loss, and sometimes rupture of the tympanic 





Pneumonia: The inflammation of one or both lungs, with dense areas of lung 
inflammation. It is a lower respiratory tract infection associated with typical 
inflammation clinical sign such as fever, and problem breathing. (Gereige & Laufer, 
2013)  
Respiratory epithelium: The tissue lining the mouth, nose, throat, and trachea. 
This lining acts as a barrier between the air coming into the body and the inner tissues of 
the respiratory mechanism, and it also serves to warm, clean, and moisten the air in 
preparation for its arrival in the lungs (McDowell, Barrett, Glavin, Harris, & Trump, 
1978).    
Septicemia: A term referring to the presence of pathogenic organisms in the 
bloodstream, leading to sepsis (Stibich, 2014).  
Serotype: A category into which material, usually a bacterium, is placed based on 
its serological activity, in terms of the antigens it contains or the antibodies produced 
against it (CDC, 2014). 
Vaccine: A preparation of killed microorganisms, living attenuated organisms, or 
a living fully virulent organism that is administered to produce or artificially increase 
immunity to a particular disease. Vaccines are made of a microorganism that resembles 
the disease causing one. (WHO, 2014). 
Assumptions 
The following assumptions were made about this study:  
1. The study sample was children who have visited one of the three sentinel 





Kinshasa; province of Kinshasa; and the hospital of Sendwe in the town of 
Lubumbashi, Province of Katanga. 
2. It was assumed that children visiting the sentinel surveillance sites had not 
biased the study, and that the archival data used were of a good quality. 
3. It was presumed that the instruments used were the appropriate means for 
measuring the variables chosen.  
4. The generalizability of this study may have been good for similar 
populations of provinces having introduced the vaccine and those having 
not introduced.  
5. The study was enhanced by measuring the immunization status of the 
study participants.   
6. The vaccination status with the number of doses may have reflected the 
immunization responses. 
7. Objective immunization status measures may have helped identify those at 
risk for pneumococcal invasive diseases after demonstrating the impact of 
the vaccine.  
Scope and Delimitations 
The scope of the study was the pneumococcal vaccination of young children in 
the province of Kinshasa in the DRC and whether or not children were better protected 
from pneumococcal disease when compared to other DRC cities and provinces that have 
not yet routinely adopted pneumococcal vaccine. The time period was 2009 to July 2013. 





1. The study was delimited to an archival, quantitative, correlational, quasi-
experimental design. 
2. The study was delimited to the years 2009-July 2013 when pneumococcal 
vaccination data for Kinshasa were collected and made publically 
available. 
3. The study was delimited to the data abstracted from the sentinel 
surveillance data on pneumococcal illness. 
4. The study was delimited to data collected and provided by the ministry of 
health of the Democratic Republic of Congo. 
Any provision, condition, variable, or subject not specified was considered beyond the 
scope of this study. 
Limitations  
The following limitations were recognized in this study: 
1. Not all cities/provinces in the DRC reported the percentage of 
pneumococcal vaccinated children. 
2. This study used archival data provided by the ministry of health of the 
DRC from 2009 to July 2013 for pneumococcal disease.   
3. This is a quasi-experimental study that provided information in a limited 
time frame and may not have predicted future vaccination rates.  
4. A weighted average of pneumococcal vaccination rates for children was 
used to estimate the percentage of children where there was more than one 





5. Variations in pneumococcal vaccine effectiveness within different disease 
seasons, if appropriate, were taken into account. 
6. Data on the vaccination status and number of doses received were not 
collected; therefore, the epidemiology principle of “dose-response” could 
not be assessed.  
Significance 
This study was significant because it had the potential to demonstrate the 
effectiveness of controlling a vaccine preventable disease in a part of the world where the 
disease is still problematic with a highly effective vaccine for children 5 years of age or 
under. The vaccine has the potential to eliminate many sick children and unnecessary 
deaths due to pneumococcal infections, thus creating positive social change. This 
research study might play a part in the decision-making process relative to pneumococcal 
disease burden in the DRC and may assist with the decision to replicate the program in 
other provinces in the DRC and/or other African countries (Levine et al., 2006). It might 
also help to know the impact of the PCV 13 on the different pneumococcal circulating 
serotypes in DRC. The outcome of this study might help improve the quality of the 
program because the information obtained can help researchers in developing new 
vaccines.  
Summary and Transition 
Researchers have established vaccination as an essential ingredient for preventing 
vaccine preventable diseases. Vaccines induce protection by producing antibodies to fight 
against the germs that enter the body, therefore helping reduce morbidity and mortality 





public health achievements in the 20th century (CDC, 2013). There are many infectious 
diseases that are vaccine-preventable, and invasive pneumococcal disease is one of them. 
A child who is completely vaccinated acquires immunity against vaccine preventable 
diseases (CDC, 2013). 
 PCV13 protects against the most disease-causing serotypes of streptococcus 
pneumoniae. Introducing the vaccine into the routine childhood vaccination schedule 
throughout the entire DRC might help reduce the burden of pneumococcal diseases 
among the country’s children and promote a healthy population. 
In Chapter 2. I present a review of the existing literature and how new research is 
suggesting an association between the use of the PCV13 vaccine in the childhood 
immunization schedule and the reduction in the incidence of invasive pneumococcal 
















Chapter 2: Literature Review 
Introduction 
Invasive pneumococcal diseases are deadly diseases that could be prevented with 
available vaccines. The WHO, (2013) estimated that 800,000 children under the age of 5 
die each year of invasive pneumococcal disease. Childhood vaccination against this 
disease reduces morbidity and mortality (CDC, 2012). According to the immunization 
authority, pneumococcal conjugate vaccine (PCV13) was introduced in the DRC in 2011; 
however, all provinces have not yet been vaccinated. The vaccine introduction was 
completed in only 5 of the 11 provinces of the country. There was the need to know the 
impact of the vaccine in order to confidently continue with the introduction in the 
remaining provinces.  
 The purpose of this study was to determine whether there was an association 
between the introduction of PCV13 and new cases of pneumococcal disease in two 
provinces in central Africa. In the literature review, I establish the need for continued 
research concerning the value of the pneumococcal conjugate vaccine that helps the 
individual fight off the invading bacteria, thereby protecting him or her from harmful 
invasive pneumococcal diseases. The impact of the vaccine on the circulating serotypes 
in a geographical area is a relatively new field of research being conducted because the 
available vaccines only contain 13 of the 93 serotypes existent. Scholars have examined 
the cost effectiveness of the pneumococcal conjugate vaccine, its impact in the reduction 
of mortality and morbidity, as well as the importance of prevention through vaccination 





 The number of doses of vaccine is important for the development of immunity to 
the disease. The development of immunity through antibody creation is instrumental in 
the recipient’s ability to resist infection, thereby staying healthy and exempting him or 
her from deadly vaccine preventable diseases. Vaccination with the three doses of 
pneumococcal conjugate vaccine at 2, 4, and 6 months of age is followed up with a 
booster dose when the antibody concentration declines (Käyhty, and Eskola, 1996). The 
decision to give a booster vaccination is based on the rate of decline and persistence or 
not of immunologic memory (Akinsola et al., 2012). 
This chapter provides a review of the evolution of the antibody theory, 
specifically the inherent importance of the development of immunity after receiving the 
appropriate vaccine inoculation. In addition, pneumococcal conjugate vaccine impacts 
research relating to the questions addressed in this study. Research on the diseases caused 
by the streptococcus pneumonia, the different disease causing serotypes of the bacteria, 
the serotypes covered by the available vaccines, and their role in the development of 
invasive pneumococcal diseases were incorporated into this chapter. In order to have an 
objective discussion of the literature, this chapter includes a discussion of research that 
challenges some of the outcomes of research in these areas. The chapter culminates with 
an explanation of how past research influenced this study.   
Literature Search Strategy 
 A search of literature was conducted digitally through electronic medical 
databases such as Pub Med (NCBI and MeSH databases), Walden library databases 
(Academic Search Complete and ScienceDirect), and Google scholar. The list of search 





streptococcus pneumonia serotypes, burden of pneumococcal diseases, pneumococcal 
conjugate vaccines, and impact of the vaccines on circulating pneumococcal strains. Full 
text peer-reviewed articles spanning from 1990 to the last 5 years were obtained digitally 
and reviewed for this study.  
Theoretical Foundation 
 The theoretical framework for this study was the epidemic model supported by 
the concept of herd immunity. An epidemic model is based on the following assumptions: 
(a) infectious disease is transmitted by person-to-person contact only; (b) persons 
susceptible to the disease will develop the disease after contact with an infected person, 
thereby acquiring immunity to the illness; (c) there is a fixed probability of coming in 
contact with an infectious person; (d) the population has no contact with anyone outside 
the community; and (e) the conditions remain constant throughout the epidemic (Fine, 
1977). Herd immunity or threshold protects susceptible individuals in a community from 
disease assuming there is a minimum vaccination threshold (Libster & Edwards, 2011, p. 
163; Piedra et al., 2005). Herd immunity applies to infectious disease that can be 
transmitted from person to person. 
Literature Review 
Antibody Theory 
 According to the antibody theory, health is the multidimensional product of 
constant interactions between biological mechanisms, psychological processes, and the 
immune system. The antibody theory, as developed by Brein, Haurowitz, Mudd, 
Alexander, and Pauling, based on the antigen-template theory assumes that antibodies 





antibody molecule toward the antigen is due to a complementarity in structure derived 
from the folding of a part of the polypeptide chain of a globulin molecule in direct 
contact with a determinant or haptenic region of the antigen. The antigen serves as a 
template in the final stage of formation of a globulin molecule. According to the antibody 
theory, there is a similarity between antibody formation and adaptive enzyme formation 
which allows for the continued production of antibody after the antigen has disappeared 
from the body (Jerne, 1955). A renewed contact with the antigen stimulates the 
replication of these enzymic units. Circulating antibody molecules are partial replicas of 
the modified enzymic units, carrying specificity but lacking enzymatic action (Jerne, 
1955).  
 Vaccines provide protection through immune receptors called antibody in the 
presence of a pathogen. The antibodies are produced by the B lymphocytes that can bind 
to a pathogen (Siegrist, nd). The T lymphocytes play a role in limiting the spread of the 
infection by recognizing and killing infected cells or secreting specific antiviral 
cytokines. Most vaccines involve both B and T cells responses (Siegrist, 2008). 
In the DRC, the clinical and laboratory diagnostic of pneumococcal diseases are 






WHO Coordinated Invasive Bacterial Vaccine Preventable Diseases (IB-VPD) 










































Any child aged 0-59 months admitted to a sentinel hospital 
conducting surveillance with sudden onset of fever (> 38.5 
°C rectal or 38.0 °C axillary) and one of the following signs: 
neck stiffness, altered consciousness with no other 
alternative diagnosis, or other meningeal sign 
Or 
Every patient less than 5 years of age hospitalized with a 
clinical diagnosis of meningitis. 
 
 
A suspected meningitis case (as defined above) with CSF 
examination showing at least one of the following: 
 Turbid appearance; 
 Leukocytosis (> 100 cells/mm3); 
 Leukocytosis (10-100 cells/ mm3) AND either an 
elevated protein (>100 mg/dl) or decreased glucose 
(< 40 mg/dl) 
Note: if protein and glucose results are not available, 
diagnose using the first two conditions (i.e. turbid 































A suspected meningitis case that is laboratory-confirmed by 
growing (i.e. culturing) or identifying (i.e. by Gram stain, 
antigen detection, immunochromotography, PCR or other 
methods) a bacterial pathogen (Hib, pneumococcus or 
meningococcus) in the CSF or from the blood in a child with 








WHO Coordinated Invasive Bacterial Vaccine Preventable Diseases (IB-VPD) 


































Any child aged 0-59 months admitted to a sentinel hospital 
conducting surveillance, demonstrating a cough or difficulty 
breathing and displaying fast breathing when calm (as 
defined by age): 
Age 0 to <2 months: 60 breaths/minute or more 
Age 2 to < 12 months: 50 breaths/minute or more 
Age 12 to <59 months: 40 breaths/minute or more 
 
Any child aged 0-59 months admitted to a sentinel hospital 
conducting surveillance, demonstrating a cough or difficulty 
breathing and displaying one or more of the following:  





Stridor when calm 
 
Pneumonia in a patient with a chest radiograph showing an 
infiltrate consistent with pneumonia, i.e., dense, fluffy 











Any child aged 0-59 months admitted to a sentinel hospital 
conducting surveillance with the presence of at least 2 of the 
following danger signs and without meningitis nor 
pneumonia clinical syndrome: 
Inability to drink or breastfeed 
Vomiting everything 
Convulsions (except in malaria endemic areas) 
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 Streptococcus pneumonia, the bacteria responsible for the pneumococcal 
infections, colonize the nasopharynx before either infecting the mucosa causing otitis, 
pneumonia, or the blood stream causing invasive pneumococcal diseases (Nurhonen, 
Cheng, & Auranen, 2013). Pneumococcal diseases cause severe clinical manifestations in 
children such as pneumonia, meningitis, sepsis, and bone and joint infections. The 
bacterium is responsible for most severe cause of bacterial meningitis in children less 
than 5 years of age (Knoll et al., 2009). Infection with the bacteria can lead to extreme 
illness and cause loss of life in most cases. 
 Pneumococcal diseases are classified into two groups: the invasive pneumococcal 
diseases (IPDs) and the noninvasive pneumococcal diseases (Ercan, Severge, Topkaya, 
Ercan, & Altınkaya, 2011). The case is classified as IPD when the bacteria are isolated 
from the blood, cerebro spinal fluid, or pleural fluid and manifesting into meningitis, 
sepsis, or bacteremia pneumonia (Adalata, & Riordanb, 2007). The noninvasive disease 
is manifested into otitis media, sinusitis, and bronchitis (Ansaldi et al., 2008). 
Meningitis 
Less common but severe forms of pneumococcal disease are often deadly or leave 
the child with a permanent disability. Meningitis or inflammation of the meninges is an 
infectious disease affecting the brain membrane and spinal cord that is caused by either 
neisseria meningitides or streptococcus pneumonia in most of the cases (Uiterwijk & 
Koehler, 2012). The disease is characterized by fever, headache, stiff neck, nausea, 
vomiting, photophobia, and altered consciousness. The diagnostic is done by analyzing a 





bacteria (Uiterwijk & Koehler, 2012). Meningitis can be treated with antibiotics 
(Uiterwijk & Koehler, 2012).    
Pneumonia 
The most common severe form of pneumococcal diseases occurs when the 
bacteria enters the blood stream and subsequently invades other sites of the body such as 
the cerebrospinal fluid (CDC, 2014). Pneumonia is an infection of the lungs caused by 
viruses, bacteria, and fungi (CDC, 2014). The most common pneumonia is caused by the 
bacteria streptococcus pneumonia (CDC, 2014). Children are most at risk for pneumonia. 
The disease is the leading cause of death in children less than 5 years of age worldwide 
(CDC, 2014). 
Otitis Media 
Otitis media is an inflammatory infection of the middle ear caused by 
streptococcus pneumonia and is characterized by a collection of fluid (Stephen, 1995). It 
is one of the noninvasive forms of pneumococcal diseases (Stephen, 1995).  
Serotypes of the Streptococcus pneumonia 
Immunochemistry is used with the differentiation of streptococcus pneumonia 
into over 93 serotypes grouped into about 48 serogroups. Of those 93-plus serotypes, 
only about 15 cause most of the invasive diseases in the world (Onwubiko, Shires, Quin, 
Swiatlo, & McDaniel, 2007). Currently the conjugate vaccines available only contain 13 
serotypes; there is a need for more vaccine research, but developing a vaccine that will 
cover the most frequent serotypes found in invasive diseases is difficult because serotype 





Surveillance with the identification of serotypes in countries is important to determine the 
vaccine impact after introduction (Hinds et al., nd). 
Pneumococcal vaccines 
Pneumococcal disease prevention is becoming important as more serotypes are 
becoming resistant to antibiotics (Ochoa et al., 2010). Two types of vaccines are currently 
available for pneumococcal diseases prevention: the pneumococcal polysaccharide 
vaccines and the pneumococcal conjugate vaccines, the latter being the subject of this 
study.   
 Although polysaccharides have been available since the mid-1980s, they are not 
recommended for use in children < 2 years probably due to their immature immune 
system. In addition, the immune response after vaccination with the polysaccharide is B-
cell-dependent with release of IGM as opposed to conjugates vaccines which elicits 
mucosal immune response by induction of IgA antibodies (Pletz et al., 2008). Success in 
the vaccination of young children came with the development of pneumococcal conjugate 
vaccines starting with the seven valents which included the seven most pediatric disease 
causing serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F). Compared to polysaccharides 
covering 23 serotypes, conjugates vaccines have a low coverage of pneumococcal 
serotypes with only 50% protection for infections in adults; although they are effective in 
infant against invasive pneumococcal diseases (Pletz et al., 2008). 
The pneumococcal polysaccharides vaccine (PPV) contains 23 of the over 90 
serotypes of the streptococcus pneumoniae bacteria which were responsible for about 
90% of most invasive diseases in the United States and constitute the most antibiotics 





effective and inexpensive, because of the need to revaccinate in older adults in whom the 
effectiveness is only 50 to 70% due to a decline in antibody over time; and its 
ineffectiveness in children less than 2 years of age because of the immaturity of their B 
cells (Artz, Ershler, & Longo, 2003).  
To respond to this problem, alternate vaccines called pneumococcal conjugate 
vaccines are being developed by linking the polysaccharide antigens with immunogenic 
carrier proteins, activating a response from the T cells and improving the antibody quality 
(Chiu, & Mclntyre, 2013). This vaccine not only provides coverage for younger children, 
but also longer and durable protection against the strains included in it (Chiu, & 
Mclntyre, 2013). The first PCV was licensed in the year 2000 after scholars showed a 
decrease in invasive pneumococcal diseases in general and somewhat of otitis media in 
children (Chiu, & Mclntyre, 2013). Beside the conjugation of PPV, studies are underway 
to develop another vaccine called pneumococcal protein vaccine that will eventually 
cover all serotypes of the bacteria with the potential to stimulate immunologic memory 
(Artz et al., 2003). Licensing of the PCV vaccines began with the seven valent one 
(PCV7) in the year 2000 for the United States and in 2001 or later for Europe and the rest 
of the world. This vaccine covered about 80% of the most invasive disease causing 
pneumococcal pneumoniae strains in children in the United States and the majority of the 
disease causing around the world (Weil-Olivier, van der Linden, de Schutter, Dagan, & 
Mantovani, 2012.  
 The pneumococcal conjugate vaccine is one of the greatest public health 
successes in the past decade. In light of the success of the vaccine in drastically reducing 





include more serotypes leading to the development and licensing of PCV10 and PCV13 
respectively from 2008 and 2010 and later in countries. PCV13 recommended use is as 
follows (Paradiso, 2011):    
1. For all children as a 4-dose series at 2, 4, 6, and 12–15 months of age. 
2. Children, 24 months of age who have received >1 dose of PCV7 should complete 
the immunization series with PCV13. 
3. Children 14–59 months who are fully vaccinated with PCV7 should receive a 
single dose of PCV13. 
4. Children with underlying medical conditions increasing susceptibility to 
pneumococcal infection who are fully vaccinated with PCV7 should receive a 
single dose of PCV13. 
Impact of Vaccines on the Circulating Strains 
PPV was shown to have reduced the disease incidence in adults 65 years or older 
and children 2 years and older with certain conditions such as heart disease. According to 
the Centers for Disease Control and Prevention (2012), healthy adults who get the PPV 
vaccine develop protection within 2 to 3 weeks (Dagan, 2009). PCV has been shown in 
studies to be effective against invasive and non-invasive pneumococcal diseases. It was 
shown in the literature that PCV reduced the burden of antibiotic resistant streptococcus 
pneumoniae serotypes (Dagan, 2009). Particularly vaccination with PVC 7 has been 
demonstrated to cause a reduction of the nasopharyngeal carriage types of the penicillin 
resistant serotypes of streptococcus (Dagan, 2009).   
 In a 2009 publication the impact of PCV 7 vaccine on the strains of streptococcus 





2005 were compared regarding the circulating strains and the antibiotic resistant of them 
as well as the impact of the PCV7 on them. The results showed an increased prevalence 
of isolates with intermediate penicillin resistance and erythromycin resistance 
respectively from 12.7% to 17.9% and from 25.7% to 29.1% and a decreased prevalence 
of penicillin resistant isolates from 21.5% to 14.6% between the two respiratory illness 
seasons; the prevalence of multidrug resistance did not change. The study also showed 
that there was a change in the Streptococcus Pneumoniae population between the two 
seasons with an increase of the serotypes 19A (14.5%), 3 (11.2%), 6A (7.1%), 19F (7%) 
and 11A (6%) for the period 2004-2005 of whom only 16.3% are included in the PCV 7 
vaccine; and a decrease in the prevalence of most of the vaccine containing serotypes.   
 In conclusion PCV7 has been found to have an impact on the vaccine containing 
serotypes (Richter et al, 2009). A study conducted by CDC  (2012) in the US have 
showed that PCV7 vaccines are highly effective (90%) in younger healthy children 
helping disease incidence decrease by 99% for the vaccine serotypes and an increase in 
the incidence of invasive pneumococcal diseases due to the serotypes not included in the 
vaccine. 
Implications of Past Research on Present Research 
 The impact of pneumococcal vaccines is well documented within the fields of 
immunization and vaccine preventable diseases. Vaccination and immunization are 
intertwined with disease prevention. The antibody theory has broadened our 
understanding of the influence of vaccines on disease prevention (Siegrist, 2008). The 
physiological response to an infection and the ability to prevent it depend upon the ability 





 In an attempt to better understand the physiological response to infection, 
researchers studied the human immune system. Studies began to conclude a direct 
connection between the immune system and the protection against diseases in the 
presence of infectious agents (Granoff, Gupta, Belshe, & Anderson, 1998). The presence 
of an infectious agent stimulates a physiological chain of events that begins with early-
induced responses to eliminate the infection or hold it in check until specific, acquired 
immune responses have time to develop (Granoff, Gupta, Belshe, & Anderson, 1998). 
The immune response appears to act like a signaling substance on the nervous system; 
engaging the areas of the brain that direct the induction of immunologic memory could be 
an important second mechanism of protection (Granoff, Gupta, Belshe, & Anderson, 
1998).  
 The cost effectiveness of vaccination against infections in general and 
pneumococcal diseases in particular has been demonstrated in several studies. In a study 
conducted in Sweden in 2008 to determine if vaccination with the 7 valents 
pneumococcal conjugate vaccine is a cost-effective intervention taking into account herd 
immunity has showed that protection of children can be achieved at low and moderate 
cost when herd immunity is taken into account. Using a Markov model developed by 
Wisloff et al in 2006, the authors have compared a pneumococcal vaccination program 
and a no vaccination program of a hypothetical Swedish birth cohort of 95,000 infants 
(Bergman et al, 2008).      
            O’Brien, et al. (2009) in a study attempted to determine if the burden of invasive 
pneumococcal diseases was higher in children younger than five years of age compared 





neighboring countries whenever available, results showed that Pneumococcal disease 
caused about 826 000 deaths  in children aged 1–59 months around 11% of the overall 
mortality in children less than 5 years of age. 
 Zangeneh, Baracco, & Al-Tawfiq, (2011) provided insight on the approved new 
vaccine containing emerging pneumococcal serotypes in addition to the septivalent and 
its potential to protect against most disease causing ones. Ayieko et al in their 
Assessment of Health Benefits and Cost-Effectiveness of 10-Valent and 13-Valent 
Pneumococcal Conjugate vaccination in Kenyan Children found that by investing 
annually $14million in the vaccine, 43% of infection with the disease could be avoided; 
this could help save $1.97 million in treatment cost and a 6.1 % reduction in child 
mortality. Therefore introducing the pneumococcal conjugate vaccine is highly cost 
effective (Ayieko et al., 2013). 
Literature Relating to Differing Methodologies 
 The majority of studies in the arena of the impact of the PCV13 have been 
correlational in nature due to the difficulty in measuring the vaccine effectiveness. The 
relationship between PCV vaccination and prevention against invasive pneumococcal 
diseases in children less than 5 years of age has been relatively unexplored, although the 
literature suggests a possible connection.    
 Whitney et al, (2003) provided evidence that the pneumococcal conjugate vaccine 
seven valent (PCV7) induced a decline in the invasive disease in children especially the 
less than 2 years of age and may also reduce the burden of disease in adults. They have 
examined surveillance data from the active bacterial core surveillance of the CDC for the 





introduction of the PCV-7 vaccine. Sixteen million persons were under surveillance in 
2000, of those 433,591 were less than two years of age and 652,551 were between the 
ages of two and four. The results showed a drop in the rate of invasive disease after the 
introduction of the PCV7 vaccine from an average of 24.3 cases per 100,000 persons in 
1998 and 1999 to 17.3 per 100,000 persons in 2001 with the largest decline in the less 
than 2 years group. 
 After comparing the incidence of invasive pneumococcal diseases in children less 
than 2 years of age before and after vaccination with PCV7 in a study, the authors 
observed a significant decrease of at least 60%. They have concluded that the conjugate 
vaccine is effective on children too young to receive the pneumococcal polypeptide. In 
this prospective population-based study using laboratory surveillance data, infants aged 0 
to 90 days residing in 8 US states were examined for invasive streptococcus pneumoniae 
infection during the period of July 1
st
 1997- June 30 2004. One hundred and forty-six 
cases of invasive Pneumococcal Diseases were identified of which 89 before the 
introduction of the vaccine and 57 after the introduction (Poehling et al., 2006). 
 Using a retrospective study of children admitted in a hospital in Alberta, Canada 
for complicated pneumonia over a 10 year period (1997-2007); the authors came to the 
conclusion that there was an increase in the incidence of complicated pneumonia after 
vaccination with PCV 7 with 67% of the cases accounting for the non-vaccine serotypes 
prompting the need for new vaccines covering more serotypes. It should be noted that the 
data used was 5 years before and 5 years after introduction of the PCV7. Data collected 
in the charts of inpatient children up to 17 years of age suffering from complicated 





a predominant microorganism identified with non-vaccine serotypes (Chibuk, Robinson, 
& Hartfield, 2010). 
 In a case control study, Ercan, Severge, Topkaya, Ercan, & Altınkaya, (2011) 
examined 138 children completely vaccinated with pneumococcal vaccine and 109 
unvaccinated control subjects aged 12–59 months. Data from October 2007 and April 
2008 was analyzed to determine the effect of the pneumococcal conjugate vaccine on the 
pneumococcal carriage in Turkish children. The results did not show a significant 
difference in pneumococcal carriage rate between the two groups (10.1% vs 16.5%) but 
there was long term protection against the serotypes included in the vaccine.  
 Another study using a randomized controlled trial analyzed the indirect effect of 
7-valent pneumococcal conjugate vaccine on pneumococcal carriage in newborns in rural 
Gambia. Twenty villages with infants aged 2-30 months vaccinated with PCV 7 were 
compared with ten villages as controls were sampled using nasopharyngeal swabs. The 
other villages received meningococcal conjugate vaccine; it was concluded that PCV-7 
induced a significant reduction of the vaccine type pneumococcal carriage in the 
unvaccinated infant population; the likely reduction probably came from the herd 
immunity provided by the children and adults vaccinated population (Egere et al, 2012).  
 Afonso et al, (2013) used an interrupted time-series to analyze 5 cities in Brazil 
that had good data quality and high PCV10 vaccination coverage. They used the data 
from the national hospitalization information system from January 2005 to August 2011 
to assess the PCV10 effectiveness in children 2-24 months after introduction of the 
vaccine in the national immunization program. The results showed that hospitalization of 





 A study conducted in Uruguay to determine the impact of vaccination with the 
pneumococcal conjugate vaccine concluded that the vaccine caused a reduction in the 
incidence of pneumonia in hospitalized children in Uruguay five year after the 
introduction of the vaccines (PCV7 and PCV13). Also it was concluded that the disease 
incidence reduction was higher for PCV13 compared to PCV7. In the study secondary 
surveillance data for the years 2009-2012 was used to compare incidence rate pre- PCV 
introduction and post-both PCV7 and PCV13 (Hortal, Estevan, Meny, Iraola, & Laurani, 
2014). 
Summary and Conclusions 
The success of smallpox eradication in 1979 by the World Health Organization 
and its partners brought the optimism that other childhood vaccines preventable diseases 
could be controlled, eliminated or eradicated through vaccination (Gandon & Day, 2007). 
According to the literature, the use of vaccines has helped provide protection against a 
number of childhood infections (McLean, 1998). The impact of pneumococcal vaccines 
was well documented within the fields of immunization and vaccine preventable diseases. 
This study added to the existing literature by helping to know the impact of the PCV13 
on different kinds of pneumococcal circulating serotypes in DRC. 
Chapter 3 describes the methodology used to study the research questions. This 
chapter discusses the use of chi-square test of independence and logistic regression as 
valid means to analyze the possibility of a relationship between the introduction of the 
pneumococcal conjugate vaccine in the childhood immunization schedule and the 





description of the sample population, procedures, ethical considerations, measures, and 


























Chapter 3: Research Method 
Introduction 
The purpose of this study was to determine whether there was an association 
between the introduction of PCV13 and new cases of pneumococcal disease in two 
provinces in central Africa. The pneumococcal conjugate vaccine was introduced to five 
provinces in the DRC. It was a gradual introduction that will eventually cover the whole 
country. No studies have been conducted to date that test the effectiveness of the PCV 13 
vaccine in the DRC. This study was the first to attempt to evaluate the impact that this 
vaccine has made. The study may also provide insight as to whether or not the vaccine 
campaign should be widened to include not only the remaining provinces of the DRC, but 
also in the rest of the African countries. 
Chapter 3 covers a description of the design, sampling and sample, 
instrumentation, data analysis, and ethical considerations. An overview of the study’s 
design is given including a rationale for the choice of this particular research design. The 
sample characteristics and size, as well as a description of the sampling process, are 
presented. The data collection process and analysis are also described in this chapter. 
Research Design and Rationale  
This study employed a quasi-experimental design using chi-square and logistic 
regression analysis. I examined the effect of the vaccination and age and gender at the 
intervention site (Kinshasa province) versus the control site (Katanga province) to 
determine who got the disease and who did not. The instruments used for measurement of 





regression. The research questions and the hypotheses reflect this type of analysis. The 
hypotheses, corresponding variables and statistical analysis are displayed in table 3. 
Table 3 


















































 In this quantitative secondary data analysis, I explored the relationship between 
the reduction in the number of incident cases of invasive pneumococcal disease and the 
introduction of PCV13 in the DRC. Disease incidence was compared in a province that 
introduced the vaccine, against another province that had not. The impact of the vaccine 
on circulating pneumococcal serotypes in the DRC was examined. Individuals considered 
for this study included children who lived in the DRC and who had been immunized with 
PCV13 starting in April 2011, as recorded in an official regional immunization record in 
the Kinshasa province, and a comparison group of the same age in the Katanga province 





abstracted were archival data, without personal identifying information as provided by 
the immunizing authority.  
Population 
 The research population was obtained from the archival data collected in the three 
sentinel surveillance sites in the municipalities of Kalembelembe, Kingasani in Kinshasa, 
province of Kinshasa, and the hospital of Sendwe in the town of Lubumbashi, Province 
of Katanga from 2009 to July 2013. Each case was pneumococcal positive by one of the 
following tests: agglutination test, culture, or PCR. Serotyping is conducted for some of 
these cases at the Regional Reference Lab (RRL) of MRC in Gambia. Available archival 
data were used for analysis. Permission was received from the government of the DRC 
for use of the archival data in the study (Appendix B). Participants selected were (a) 
children included in the archival surveillance data of the sentinel surveillance sites, (b) 
children of an age where the disease is common, and (c) children presumed to have had 
the symptoms of an invasive pneumococcal disease. 
Sampling and Sampling Procedures 
Archival data from 2009 to July 2013 were extracted from the DRC’s sentinel 
surveillance data set. This archived surveillance data set consisted of a representative 
sample of children who had visited surveillance sites complaining of signs and symptoms 
corresponding with the case definition of pneumococcal disease. The sample did not 









Prior to conducting a power analysis, three statistical parameters were set to 
ensure appropriateness of sample size. These parameters included power, expected effect 
size, and critical alpha. Power was referred to as the probability of finding a statistical 
difference between groups provided one existed in the sample data set. For the social 
sciences, power is typically set at 80% (Cohen, 1992). This means that there is an 80% 
probability that, given the size of the sample collected, a significant difference will be 
found. The effect size was the degree of shared variance expected between the variables 
of interest. Cohen (1992) defined effect size in terms of Cohen’s was .10 = small, .30 = 
medium, and .50 = large. 
 For this study, a medium expected effect size was adopted (i.e., .30). Critical 
alpha is the probability that a significant finding happened by chance. In the social 
sciences, critical alpha is usually set at .05 (Cohen, 1992). This means that there is only a 
5% chance that the null hypothesis is rejected, when in fact it is true. Accordingly, a 
formal power analysis was conducted using the following parameters: (a) power = .80, 
(b) effect size = .30, and (c) alpha = .05. Thus, using G*Power 3.0.10 (a sample size 
power analysis program), a minimum of 88 participants was needed to produce an 80% 
probability of rejecting the null hypothesis (Faul, Erdfelder, Lang, & Buchner, 2007).  
Procedure for Data Abstraction  
 Data were abstracted from the surveillance system; chosen children included in 
the DRC’s three sentinels’ sites data for pneumococcal surveillance and treatment 
(Kingasani and Kalembelebe in the province of Kinshasa and Sendwe in the province of 





pneumococcal infections in the three hospitals were not included in the study. The 
variables of interest to test the hypotheses were age, gender, location, and lab results. 
These archival data were originally collected using a case investigation form for 
pneumococcal disease designed by the DRC’s ministry of health. The case investigation 
form used inquiries about some general information, clinical information, vaccination 
status, and outcome at discharge for each participant. The questionnaire also collected 
information about the national lab result, the regional lab result, and the antimicrobial 
sensibility test result. A copy of the case investigation form is provided in Appendix C. In 
some cases, some participants had antibiotic treatment before the collection of cerebro 
spinal fluid, possibly influencing the lab result. The data collected during the child’s visit 
in one of the sentinel sites was part of the normal surveillance activity as prescribed by 
the immunization authority; therefore, no informed consent was necessary.   
 The questionnaire was scaled at the ordinal scale level. The data were provided 
with the identifiers stripped making all results anonymous. All data were extracted from 
the surveillance system and recorded using Microsoft Access and Excel. Statistical 
Package for the Social Sciences (SPSS) software program was used to analyze the data. 
Data analyses were conducted on the entire data set after screening for missing values 
and outliers. 
Instrumentation 
 In the DRC, the surveillance system is operated by the ministry of health with the 
technical and financial support of the WHO’s country office. The country is subdivided 
into health zones comprised of health centers and referral hospitals. Suspect cases are 





applicable; the sample is then sent to the laboratory for analysis. The data are scrubbed 
and entered by the data managers at each level. For this study, the data abstracted were 
collected in the three sentinel surveillance sites for the years 2009- July 2013. This is a 
credible source of data for pneumococcal disease in the DRC, as the sentinel sites are the 
places where most of the suspected pneumococcal disease patients are referred. 
All data were obtained from the DRC’s ministry of health. A letter was sent to the 
immunization authority requesting data and permission to use available data in this study. 
The letter was stamped, approved, and returned (Appendix B). As mentioned above, the 
data came from the three sentinel sites were suspect cases for pneumococcal diseases 
visit and were hospitalized.  
Operationalization of Constructs 
Number of instances (observed, not observed). Number of instances (observed, 
not observed) is defined as number of cases or occurrences determined by scientific 
observation (Ammer, 2013).  Number of instances (observed, not observed) was 
measured at the nominal level. Part 5 on the case investigation form was used to measure 
number of instances (observed, not observed) for invasive pneumococcal disease. Each 
question on the case investigation survey was scaled on a nominal scale with results from 
different tests specifically culture LCR, Latex, and PCR. 1 = Influenzae, 2 = S. 
pneumoniae, 3 = N. meningitidis, 4 = other organism, 5 = Negative. Number of instances 
(observed, not observed) was extracted from archival sources, meaning that the data were 
gathered at a previous time.    
Province type (Kinshasa, Katanga). Province type is defined as a territory 





n.d.). Province type (Kinshasa, Katanga) was measured at the nominal level: 1 = 
Kinshasa and 2 = Katanga. Questions included in Part 1, providing the general 
information on the case investigation survey questionnaire, were used to measure 
province type (Kinshasa, Katanga). Each question on the case investigation questionnaire 
was scaled at the nominal level. Province type (Kinshasa, Katanga) was extracted from 
archival sources, meaning the data were gathered at a previous time.    
 Sex. Sex is defined as either of the two main categories (male and female) into 
which humans and most other living things are divided on the basis of their reproductive 
functions. Sex is used to refer to the biological function (Gentile, 1993). Sex was 
measured at the nominal level. Part 1 of the questions on the case investigation form was 
used to measure sex: 1 = male, and 2 = female. Sex was extracted from archival sources, 
meaning the data were gathered at a previous time.    
Table 4 
Operationization of Constructs 
Variable Variable Values  Questions 
Province type Kinshasa/ Katanga Part 1 
Number of instances Observed/not observed Part 5 
Sex 
Age group 
1=Male   2= Female 








Data Analysis Plan 
The data were analyzed using the SPSS version 21 to evaluate the impact of the 
pneumococcal conjugate vaccine. The aim was to determine whether or not the 
introduction of the pneumococcal conjugate vaccine reduced invasive pneumococcal 
disease incidence. SPSS 21.0 was used to conduct and tabulate data cleaning and 
analyses of the archival data and to provide summary statistics where applicable 
including the mean, central tendency, variance, and standard deviation. Logistic 
regression analyses were used to evaluate the research questions and to assess whether 
the number of incident cases increased or decreased with age and gender, (observed, not 
observed) and province type (Kinshasa, Katanga). Archival data were obtained on 
number of incident cases of invasive pneumococcal disease by province type to create a 2 
x 2 contingency table. Logistic regression was appropriate to analyze the impact of 
vaccination on the disease incidence, given the variables (province type and number of 
incidence) were scaled at the nominal level.  
RQ1: What is the difference in the number of incident cases of invasive 
pneumococcal disease in children between the Kinshasa province following the 
introduction of PCV13 and a comparison group in the Katanga province where the 
vaccine was not introduced? 
Directional Hypothesis 1:  
H01: There is no difference in the number of incident cases of invasive 
pneumococcal disease in children between the Kinshasa province following the 





Ha1: Children in Kinshasa province where the PCV 13 was introduced showed a 
decrease in the number of incident cases of invasive pneumococcal disease as compared 
to the children of the same age in the Katanga province where the vaccine was not 
introduced. 
 Dependent variable: Number of incident cases (observed, not observed) 
 Independent variable: province type: (Kinshasa, Katanga) 
 Statistical analysis: Chi-square test of independence 
RQ2: Is there an association between age and incident cases of invasive 
pneumococcal disease in children among the Kinshasa province (PCV13) and Katanga 
province (control)?   
Directional Hypothesis 2: 
H02: There is no association between age and incident cases of invasive 
pneumococcal disease in children controlling for province (intervention vs. control) 
Ha2: Older children (2-5 years) were more likely to contract invasive 
pneumococcal disease in the control province compared to the PCV13 intervention 
province 
 Dependent variable: Number of incident cases (observed, not observed) 
 Independent variable: Province type: (Kinshasa, Katanga) 
 Covariate: Age 





RQ3: Is there an association between gender and incident cases of invasive 
pneumococcal disease in children among the Kinshasa province (PCV13) and Katanga 
province (control)? 
Directional Hypothesis 3: 
H03: There is no association between gender and incident cases of invasive 
pneumococcal disease in children controlling for province (intervention vs. control) 
Ha3: Males were more likely to contract invasive pneumococcal disease in the 
control province compared to the PCV13 intervention province. 
 Dependent variable: Number of incident cases (observed, not observed) 
 Independent variable: Province type: (Kinshasa, Katanga) 
 Covariate: Gender 
 Statistical analysis: Logistic regression  
Threats to Validity 
External Validity 
The sample may not have been the best representation of the population, because 
it only included patients who visited three hospitals among many; however, it was 
assumed to be representative because the three hospitals were chosen for pneumococcal 
diseases referral sites, and the most important information was the lab result. 
Additionally, the timing of the data collection could affect the way people were thinking 
when taking the survey. Finally, the condition of the sick child could have been a 
distraction for the parents; people might have wanted the health care worker to quickly 







Chi-square and logistic regression might not have been the only options to test the 
research questions, but they were the best options and the most accurate inferential 
statistical tests for this study because I was trying to determine if there was a significant 
association between a binomial and a categorical variable. Also, the immunization status 
might have been confounding; children might present the disease even though they are 
vaccinated, but they might not have had the appropriate number of doses to be 
immunized. Also, the quantitative design used in this study to answer the research 
questions might not have been exhaustive; this study has benefited from a qualitative 
aspect in describing the circulating serotypes of pneumococcal disease in the DRC to see 
if they were covered in the PCV 13 vaccine.   
Ethical Procedures 
 The data abstracted for this study were archival surveillance data without personal 
identifying information, as provided by the immunizing authority. The data had unique 
identification codes. The data were obtained from the ministry of health. Permission was 
received from the government of the DRC for use of the archival data in the study 
(Appendix B). Walden IRB approval was sought after approval of the proposal and was 
obtained, the IRB approval number was 09-04-15-0202213. I reviewed archival data in 
electronic copies; therefore, there was no direct contact with the participants. The data 
were cleaned before analysis and will be permanently deleted from my computer 5 years 





Summary and Transition 
 I described the methodology in Chapter 3 to help me to understand the 
relationship between the vaccination with PCV 13 and the reduction of pneumococcal 
disease in the DRC. In this chapter, the use of chi square analysis and logistic regression 
as valid means to analyze was discussed, as well as threat to validity, the ethical 
concerns, and the procedure for data abstraction. Chapter 4 covers the data abstraction 





















Chapter 4: Result 
Introduction 
The purpose of this study was to determine whether there was an association 
between the introduction of PCV13 and new cases of pneumococcal disease in two 
provinces in central Africa. I examined the relationship between DRC provinces’ 
childhood immunization rates for pneumococcal vaccine and the incidence of invasive 
pneumococcal disease. The research involved a sample of children who lived in the DRC 
and who were immunized with PCV13 starting in April 2011 as recorded in an official 
regional immunization record in the Kinshasa province and a comparison group of the 
same age in the Katanga province where the vaccine was not introduced. The research 
population was obtained from the archival data collected in the three sentinel surveillance 
sites in the municipalities of Kalembelembe, Kingasani in Kinshasa, province of 
Kinshasa, and the hospital of Sendwe in the town of Lubumbashi, province of Katanga 
from 2009 to July 2013. Three research questions were used to guide this quantitative 
study. The variables of interest included age, gender, location, and lab results. 
This chapter starts with a summary of the applied statistical methods and the 
results consisting of a detailed description of the evaluated participants. I then present the 
descriptive statistics of the sample and a review of the independent variables in relation to 
the dependent variable. The descriptive statistics of the sample are followed by the data 
analyses using a chi square test of independence and logistic regression to determine if 
the vaccination made a difference in the incidence of pneumococcal disease in the 
population moderated by sex, gender, and province type. Finally, this chapter concludes 






Prior to analyzing the research questions, data screening and data cleaning were 
undertaken to ensure the variables of interest met appropriate statistical assumptions. 
Upon review, it was found that 110 participants of the 490 in the data set were missing 
critical information such as age, gender, or lab results. These participants were removed 
from the analysis. The total number of participants used in the study was 380. 
Description of the Sample 
This study’s sample consisted of 380 children who were 5 years of age or under 
located in the DRC who have visited surveillance sites complaining of signs and 
symptoms that correspond with the case definition of pneumococcal disease during 
2009–July 2013. Data were abstracted from a valid sample of 380 participants. 
Specifically, there was not much difference between the number of participants who were 
males (51.1%, n = 194) and those who were females (48.9%, n =186); additionally, 
64.2% of the participants were under 2-years-old (n =244), 35.8% were between 2- and 
5-years-old (n = 136), and 21.6% of the participants came from the province of Katanga 
(n = 82) and 78.4% came from the province of Kinshasa (n = 298). Described in Table 5 












Frequency and Percent Statistics of Participants’ Gender, Age Groups, and Province 
Type 
Variables                                              Frequency                                           Percent 
Gender                                                         
   Male                                                          194                                                   51.1 
   Female                                                       186                                                   48.9 
Age Groups 
   < 2 years                                                    244                                                   64.2 
   2 – 5 years                                                 136                                                   35.8 
Province type 
   Katanga                                                       82                                                    21.6 
   Kinshasa                                                    298                                                    78.4 
Note: total N= 380 
Table 6 
Frequency of Participants’ Gender, Age Groups by Province Type 
 
        Province type 
Katanga      Kinshasa 
Total 
Gender   Male  45               149 194 






< 2 years 
 
2-5 years 
 37               149 
 
67               177 
 






     





Population and Sample 
The population of interest consisted of (a) children included in the archival 
surveillance data of the sentinel surveillance sites, (b) children of an age where the 
disease is common, and (c) children presumed to have had the symptoms of an invasive 
pneumococcal disease. The sample did not include children who had visited other 
hospitals in the provinces of Kinshasa and Katanga. 
Analysis of Research Questions  
The research questions were evaluated using chi-square test of independence and 
logistic regression to determine if there is a difference between number of children 
diagnosed with the disease (observed, not observed) and province type (Kinshasa, 
Katanga ), gender (male, female), and age groups.  
The dependent variable for the analyses was the number of incident cases as 
measured by the case investigation questionnaire and defined in Chapter 3. The 
independent variables were province (Katanga, Kinshasa) type, gender (male, female), 
and age groups.  
Research Questions and Hypotheses. 
 The research questions were the following: 
 
RQ1: What is the difference in the number of incident cases of invasive 
pneumococcal disease in children between the Kinshasa province following the 
introduction of PCV13 and a comparison group in the Katanga province where the 
vaccine was not introduced? 





H01: There is no difference in the number of incident cases of invasive 
pneumococcal disease in children between the Kinshasa province following the 
introduction of PCV 13 and the Katanga province where the vaccine was not introduced.  
Ha1: Children in Kinshasa province where the PCV 13 was introduced showed a 
decrease in the number of incident cases of invasive pneumococcal disease as compared 
to the children of the same age in the Katanga province where the vaccine was not 
introduced. 
 Dependent variable: Number of incident cases (observed, not observed) 
 Independent variable: province type: (Kinshasa, Katanga) 
 Statistical analysis: Chi-square test of independence 
RQ2: Is there an association between age and incident cases of invasive 
pneumococcal disease in children among the Kinshasa province (PCV13) and Katanga 
province (control)?   
Directional Hypothesis 2: 
H02: There is no association between age and incident cases of invasive 
pneumococcal disease in children controlling for province (intervention vs. control) 
Ha2: Older children (2-5 years) were more likely to contract invasive 
pneumococcal disease in the control province compared to the PCV13 intervention 
province 
 Dependent variable: Number of incident cases (observed, not observed) 
 Independent variable: Province type: (Kinshasa, Katanga) 





 Statistical analysis: Logistic regression 
RQ3: Is there an association between gender and incident cases of invasive 
pneumococcal disease in children among the Kinshasa province (PCV13) and Katanga 
province (control)? 
Directional Hypothesis 3: 
H03: There is no association between gender and incident cases of invasive 
pneumococcal disease in children controlling for province (intervention vs. control) 
Ha3: Males were more likely to contract invasive pneumococcal disease in the 
control province compared to the PCV13 intervention province. 
 Dependent variable: Number of incident cases (observed, not observed) 
 Independent variable: Province type: (Kinshasa, Katanga) 
 Covariate: Gender 
 Statistical analysis: Logistic regression 
Before conducting the following analyses, the data were assessed using an 
analytic strategy in that the variables were first evaluated for missing data, skewness and 
Kurtosis, univariate outliers, normality, and linearity. Subsequently, chi-square and 
logistic regression analyses were run to determine if any significant difference existed 
between the variables of interest. 
Chi-square test of independence analysis for research question1 
Using SPSS 21, chi-square analysis was conducted to determine if a significant 
difference existed in the number of incidence cases of invasive pneumococcal diseases in 
children between the Kinshasa province following the introduction of PCV13 vaccine 





Because P value = 0.000 < 0.05, I reject the null hypothesis. At α=0.05 level of 
significance, there is enough evidence to conclude that a significant difference existed in 
the number of incident cases of invasive pneumococcal diseases between the Kinshasa 
province following the introduction of PCV 13 vaccine and a comparison group in the 
Katanga province where the vaccine was not introduced (χ²= 12.302; p <0.001). The 
number of incident cases of invasive pneumococcal disease was significantly higher 
among children in the province of Katanga where the PCV 13 vaccine was not 
introduced. Summarized details are displayed in Tables 7 and 8. 
Table7 
2X2 Table Showing Count and Expected Count by Province Type. Final result * Province 
type Crosstabulation 




Observed Count 20 29 49 
Not Observed Count 62 269 331 











Summary of Chi-Square Analysis for Research Question 1 
 Value 
 






Pearson Chi-square 12.302a 1 .000   
Continuity 
Correctionb 
11.032 1 .001   
Likelihood Ratio 10.812 1 .001   
Fisher's Exact Test 
Linear-by-Linear 
Association 












Note: a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 
10.57. 
         b. Computed only for a 2x2 table 
        N= 380 






Figure 1: Distribution of final result by province type 
Logistic Regression Analyses 
Logistic regression analyses were conducted to determine if there were significant 
differences in number of incident cases between provinces and between males and 
females for the age groups < 2 years and 2-5 years. Specifically, Analysis 2-3 evaluated 
differences in incident cases of invasive pneumococcal disease (dependent variable). The 
independent variables were gender (male, female), age groups (<2 years old and 2 – 5 
years old), and province type (Katanga, Kinshasa). The predictor variable for the two 





moderating variable for Analysis 2 was age groups (<2-years-old and 2-5-years-old). The 
moderating variable for Analysis 3 was gender (male, female).  
Logistic Regression Analysis for research question2 
Using SPSS 22, binary logistic regression analysis was conducted to determine if 
a significant difference existed in the number of incidence cases of invasive 
pneumococcal diseases in children aged up to 5 years between the Kinshasa province 
following the introduction of PCV13 vaccine and a comparison group of the same age in 
the Katanga province where the vaccine was not introduced.  
Table 9 
Block 0: Beginning Block for Research Question 2. Iteration Historya,b,c 




Step 0 1 300.730 1.484 
2 292.262 1.855 
3 292.129 1.909 
4 292.129 1.910 
5 292.129 1.910 
Note: a. Constant is included in the model. 
           b. Initial -2 Log Likelihood: 292.129 
           c. Estimation terminated at iteration number 5 because 






Variables in the Equation 
 B S.E. Wald      df   Sig.           Exp(B) 
Step 0 Constant 1.910 .153 155.755 1 .000 6.755 
 
Table 11 
Variables not in the Equation 
 Score df Sig. 
Step 0 Variables Province type(1) 12.302 1 .000 
Ag groups(1) 4.356 1 .037 
Overall Statistics 14.383 2 .001 
 
Block 0: Beginning Block. Tables 9, 10 and 11 suggests that if I knew nothing about my 
variables and guessed that older children (2-5 years) will be more likely to contract 
invasive pneumococcal disease in the control province compared to the PCV13 
intervention province, I would be correct 87.1% of the time. The variable not in the 
equation table means that both variables improve the model, with province type slightly 
better than age groups, as both are significant and if included would add to the predictive 


















Step 1 1 291.915 1.736 -.539 -.211 
2 279.464 2.374 -.890 -.429 
3 278.925 2.570 -.985 -.543 
4 278.923 2.586 -.989 -.555 
5 278.923 2.586 -.989 -.555 
Note : a. Method: Enter 
            b. Constant is included in the model. 
            c. Initial -2 Log Likelihood: 292.129 
            d. Estimation terminated at iteration number 5 because parameter estimates 
changed by less than .001. 
Table 13 
Omnibus Tests of Model Coefficients 
 
   Chi-square   df            Sig. 
Step 1 Step 13.207 2 .001 
Block 13.207 2 .001 






Block 1 Method = Enter displayed in tables 12 and 13 present the results when the 
predictors province type and age groups are included. SPSS prints a classification table 
which shows how the classification error rate has not changed from the original 87.1%. 
By adding the variables we can still predict with 87.1% accuracy (see classification Table 





 Observed Predicted 
 Final result Percentage 
Correct  Observed Not Observed 
Step 1 Final result Observed 0 49 .0 
Not Observed 0 331 100.0 
87.1 Overall Percentage 
Note: a. The cut value is .500 
Model chi-square is used to test the overall significance. It is the difference between –
2log likelihood for the best-fitting model and –2log likelihood for the null hypothesis 
model  
There are two hypotheses to test in relation to the overall fit of the model: 
H0: The model is a good fitting model. 
H1: The model is not a good fitting model. 





In our case model chi square has 2 degrees of freedom, a value of 13.207 and a 
probability of p < 0.01. Thus, the indication is that the model has a poor fit, with the 
model containing only the constant indicating that the predictors do have a significant 
effect and create essentially a different model.  
Table 15 
Model Summary 
Step -2 Log 
likelihood 




1 278.923a .034 .064 
Note: a. Estimation terminated at iteration number 5 because 
parameter estimates changed by less than .001. 
The Model summary in table 15 provides some approximations of the coefficient of 
determination R2. 
Here the Cox and Snell’s R-Square is indicating that 3.4% of the variation in the 
dependent variable is explained by the logistic model. The Nagelkerke modification that 
does range from 0 to 1 is a more reliable measure of the relationship. Nagelkerke’s R2 is 
normally higher than the Cox and Snell measure and is the most-reported of the R-
squared estimates. In our case it is 0.064, indicating a weak relationship of 6.4% between 






Hosmer and Lemeshow Test 
Step Chi-square df Sig. 




Contingency Table for Hosmer and Lemeshow Test 
 Final result = Observed Final result = Not Observed Total 
Observed Expected Observed Expected 
Step 1 1 17 17.474 50 49.526 67 
2 3 2.526 12 12.474 15 
3 21 20.526 156 156.474 177 
4 8 8.474 113 112.526 121 
 
Tables 16 and 17 showed that Our H-L statistic has a significance of .921 which means 
that it is not statistically significant and therefore our model is quite a good fit. This 
desirable outcome of non-significance indicates that the model prediction does not 







Variables in the Equation 
   B 
 
SE Wald df Sig. Exp 
(B) 
95% CI for 
EXP (B) 







 -.989 .330 9.010 1 .003 .372 .195       .709 
 Age 
groups (1) 
 -.555 .370 2.249 1 .134 .574 .278        1.186 
 Constant  2.586 .324 63.699 1 .000 13.280  
 
Note: a. Variable(s) entered on step 1: Province type, Age groups. 
The Wald statistic displayed in table 18 has a chi-square distribution.  
In the variable in the equation table, we note that Province type contributed significantly 
to the prediction (p = .003) which is less than .05 (we reject the null hypothesis) but Age 
groups did not (p = .134), we accept the null hypothesis.  
The Exp (B) value associated with Province type is .372 meaning that participants are 0.4 
time more likely to belong to the Observed group. The Exp (B) value associated with Age 
groups is 0.574; participants are 0.6 time more likely to belong to the observed group. 
In this study age group is 0.6 times as important as province type in determining the 
decision (see above). 
Table 19 
Correlation Matrix 
 Constant Province type(1) Agegroups(1) 
Step 1 Constant 1,000 -.214 -.796 
Province type(1) -.214 1.000 -.183 






The Correlation Matrix table 19 shows the correlations between each of the predictor 
variables and the constant. 
 
             Step number: 1 
 
             Observed Groups and Predicted Probabilities 
 
     200 +                                                                                                    + 
         I                                                                                                    I 
         I                                                                                        N           I 
F        I                                                                                        N           I 
R    150 +                                                                                        N           + 
E        I                                                                                        N           I 
Q        I                                                                                        N   N       I 
U        I                                                                                        N   N       I 
E    100 +                                                                                        N   N       + 
N        I                                                                                        N   N       I 
C        I                                                                                        N   N       I 
Y        I                                                                         N              N   N       I 
      50 +                                                                         N              N   N       + 
         I                                                                         N              N   N       I 
         I                                                                         N              O   N       I 
         I                                                                         O         N    O   O       I 
Predicted ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------- 
  Prob:   0       .1        .2        .3        .4        .5        .6        .7        .8        .9         1 
  Group:  OOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN 
 
          Predicted Probability is of Membership for Not Observed 
          The Cut Value is .50 
          Symbols: O - Observed 
                   N - Not Observed 
          Each Symbol Represents 12.5 Cases. 
 
Figure 2. Probability of membership 
 
Figure 2 shows how our full model predicts membership. Accuracy is shown by the 
unusually clarity in the middle.  
Results Analysis 2 
Using SPSS 21.0, Analysis 2 was evaluated using Binary Logistic regression analysis to 
determine if a significant relationship existed between the number of incident cases 
between the Kinshasa province where PCV 13 was introduced and the Katanga province 
where the vaccine was not introduced, and if that relationship was moderated by Age 
group. Results indicated that a  
test of the full model against a constant only model was statistically significant, 





between the Kinshasa province and the Katanga province (chi square = 13.207, p < .01 
with df = 2).  
Nagelkerke’s R2 of .064 indicated a weak relationship between prediction and grouping. 
Prediction success overall was 87.1% (100% for Not observed and 0% for Observed. The 
Wald criterion demonstrated that only province type made a significant contribution to 
prediction (aOR 0.372, 95% CI 0.709-0.195, P=0.003). Age group was not a significant 
predictor (aOR 0.574, 95% CI 1.186-0.278, P= .134) 
Logistic Regression Analysis for research question 3 
Table 20 






Step 0 1 300.730 1.484 
2 292.262 1.855 
3 292.129 1.909 
4 292.129 1.910 
5 292.129 1.910 
Note: a. Constant is included in the model. 
            b. Initial -2 Log Likelihood: 292.129 
            c. Estimation terminated at iteration number 5 because 







Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 0 Constant 1.910 .153 155.755 1   .000 6.755 
 
Table 22 
Variables not in the Equation 
 Score df Sig. 
Step 0 Variables Province type(1) 12.302 1 .000 
Gender(1) .000 1 .996 
Overall Statistics 12.323 2 .002 
 
Block 0: Beginning Block. Tables 20, 21and 22 suggests that if we knew nothing about 
our variables and guessed that Males will be more likely to contract invasive 
pneumococcal disease in the control province compared to the PCV13 intervention 
province we would be correct 87.1% of the time. The variable not in the equation table 
tells us that both variables improve the model, with Province type slightly better than Age 










Block 1: Method=Enter for research question 3. Iteration Historya,b,c,d 
Iteration -2 Log 
likelihood 
Coefficients 
Constant Province type(1) Gender(1) 
Step 1 1 293.228 1.601 -.587 .020 
2 281.675 2.090 -.982 .038 
3 281.297 2.199 -1.093 .046 
4 281.296 2.205 -1.098 .046 
5 281.296 2.205 -1.098 .046 
Note : a. Method: Enter 
            b. Constant is included in the model. 
            c. Initial -2 Log Likelihood: 292.129 
            d. Estimation terminated at iteration number 5 because parameter estimates 
changed by less than .001. 
 
Table 24 
Omnibus Tests of Model Coefficients 
 Chi-square      df          Sig. 
Step 1 Step 10.834 2 .004 
Block 10.834 2 .004 






Block 1 Method = Enter. Tables 23 and 24 presents the results when the predictors 
province type and genders are included. SPSS prints a classification table which shows 
how the classification error rate has not changed from the original 87.1%. By adding the 





 Observed Predicted 
 Final result Percentage 
Correct  Observed Not 
Observed 
Step 1 Final 
result 
Observed 0 49 .0 
Not 
Observed 
0 331 100.0 
Overall Percentage   87.1 
Note: a. The cut value is .500 
Model chi-square is used to test the overall significance. It is the difference between –
2log likelihood for the best-fitting model and –2log likelihood for the null hypothesis 
model  
There are two hypotheses to test in relation to the overall fit of the model: 
H0: The model is a good fitting model. 
H1: The model is not a good fitting model. 





In our case model chi square has 2 degrees of freedom, a value of 10.834and a probability 
of p= 0.004. Thus, the indication is that the model has a poor fit, with the model 
containing only the constant indicating that the predictors do have a significant effect and 
create essentially a different model.      
Table 26 
Model Summary 
Step -2 Log 
likelihood 




1 281.296a .028 .052 
Note: a. Estimation terminated at iteration number 5 because parameter 
estimates changed by less than .001. 
 
The Model summary displayed in Table 26 provides some approximations of the 
coefficient of determination R2. 
Here the Cox and Snell’s R-Square is indicating that 2.8% of the variation in the 
dependent variable is explained by the logistic model. The Nagelkerke modification that 
does range from 0 to 1 is a more reliable measure of the relationship. Nagelkerke’s R2 is 
normally higher than the Cox and Snell measure and is the most-reported of the R-
squared estimates. In our case it is 0.052, indicating a weak relationship of 5.2% between 






Hosmer and Lemeshow Test 
Step Chi-square df Sig. 
1 .016 2 .992 
Table 28 
Contingency Table for Hosmer and Lemeshow Test 
 Final result = Observed Final result = Not Observed Total 
Observed Expected Observed Expected 
Step 1 1 9 9.198 28 27.802 37 
2 11 10.802 34 34.198 45 
3 15 14.802 134  134.198 149 
4 14 14.198 135  134.802 149 
 
As displayed in Tables 27 and 28, our H-L statistic has a significance of .992 which 
means that it is not statistically significant and therefore our model is quite a good fit. 
This desirable outcome of non-significance indicates that the model prediction does not 








Variables in the Equation 
   B 
 
SE Wald df Sig. Exp 
(B) 
95% CI for 
EXP (B) 







 -1.098 .323 11.533 1 .001 .333 .177       .628 
 Age 
groups (1) 
 .046 .312 .022 1 .882 1.047 .569        1.929 
 Constant  2.205 .248 78.905 1 .000 9.066  
Note: a. Variable(s) entered on step 1: Province type, Gender. 
 
The Wald statistic has a chi-square distribution.  
In the variable in the equation table, Table 29 we note that province type contributed 
significantly to the prediction (p = .001) which is less than .05 (we reject the null 
hypothesis) but gender did not (p = .882), we accept the null hypothesis.  
The Exp (B) value associated with Province type is .333 meaning that participants are 0.3 
time more likely to belong to the Observed group. The Exp (B) value associated with 
Gender is 1.047; participants are 1 time more likely to belong to the observed group. 











 Constant Provincetype(1) Gender(1) 
Step 1 Constant 1.000 -.445 -.616 
Provincetype(1) -.445 1.000 -.050 
Gender(1) -.616 -.050 1.000 
 
The Correlation Matrix table, Table 30 shows the correlations between each of the 
predictor variables and the constant. 
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          Each Symbol Represents 20 Cases. 
 
Figure 3: Membership probability 
Figure 3 shows how our full model predicts membership. Accuracy is shown by the 
unusually clarity in the middle.  
Results Analysis 3 
Using SPSS 21.0, Analysis 3 was evaluated using Binary Logistic regression analysis to 
determine if a significant relationship existed between the number of incident cases 
between the Kinshasa province where PCV 13 was introduced and the Katanga province 
where the vaccine was not introduced, and if that relationship was moderated by Gender. 
Results indicated that a  
test of the full model against a constant only model was statistically significant, 
indicating that there is a difference in incident cases of invasive Pneumococcal diseases 
between the Kinshasa province and the Katanga province (chi square = 10.834, p = .004 
with df = 2).  
Nagelkerke’s R2 of 0.052 indicated a weak relationship between prediction and grouping. 
Prediction success overall was 87.1% (100% for Not observed and 0% for Observed. The 
Wald criterion demonstrated that only province type made a significant contribution to 
prediction (aOR 0.333, 95% CI 0.628-0.177, P=0.001). Gender was not a significant 
predictor (aOR 1.047, 95% CI 1.929-0.569, P= 0.882).  
Descriptive analysis of S. Pneumoniae strains 
          The circulating Streptococcus Pneumoniae serotypes in the DRC include serotypes 





circulating in DRC are included in the PCV 13 vaccine. The results are displayed in table 
31. 
Table 31 
Frequency of Streptococcus Pneumoniae serotypes 
 Frequency Valid Percent Cumulative 
Percent 
 
Unknown 31 63.3 63.3 
S. Pneum ser 1 4 8.2 67.3 
S. Pneum ser 2 2           4.0 71.4 
S. Pneum ser 5 1 2.0 73.4 
S. Pneum ser 15B 1 2.0 79.6 
S. Pneum ser 19F 2 4.1 83.7 
S. Pneum ser 23F 2 4.1 87.8 
S. Pneum ser 33F 1 2.0 89.8 
S. Pneum ser 7C 1 2.0 91.8 
S. Pneum ser22F 1 2.0 93.9 
S. Pneum ser23A 1 2.0 95.9 
S. Pneum ser13 1 2.0 98.0 
S. Pneum ser19F 1 2.0 100.0 
Total 49 100.0  
 
        Table 32 and figure 4 depicts the distribution of the Streptococcus Pneumoniae 
serotypes by province type. It should be noted that serotyping was not done for all 





were unknown. The majority of serotyping was conducted for the Kinshasa province with 
only one conducted for the Katanga cases. 
Table 32 
S. Pneum serotypes by province 
                                                                  Serotypes 
Province         S.1   S.2   S.5   S.7C   S.13   S.15B   S.19F   S.22F   S.23A   S.23F   S.33F 
Katanga           0       0      1       0        0         0           0          0           0           0           0 
Kinshasa          4       2      0       1        1         1           3          1           1           2           1 
Total                4       2      1       1        1         1           3          1           1           2           1 
 
 
Figure4. Serotypes distribution by province 
          Serotypes distribution was also analyzed by province and by age groups and later 
by province and by gender. The results showed that more serotyping was done in the < 2 





the distribution is about the same for both males and females. Results are displayed in 
figures 5 and 6. When the analysis was done by crossing age groups and gender, I noted 




Figure5. Serotypes distribution by province and by age groups 
 






Figure7. Serotype distribution by gender and by age groups 
PCV13 vaccination coverage in Kinshasa province for the years 2011, 2012 and 
2013 is displayed in figure 8. The coverage for the first dose of PCV13 is good for 2012 
and 2013, it’s below 80 % for 2011, and this can be explained by the fact that 2011 was 
the first year of introduction. The third dose is barely at 80% for 2012 but less than 80% 
for 2011 and 2013; the country had a shortage of vaccine during 2013.  
 






Summary and Transition 
          In summary, pneumococcal vaccination for young children has been shown to 
prevent serious illness, hospitalizations, and even death (Rodewald et al, 1999). 
According to the World Health Organization, the risk of serious pneumococcal disease 
remains high throughout the first 24 months of life (WHO, 2013). My intent for 
researching this topic was to examine the relationship between vaccination with PCV13 
and the reduction in incidence of invasive pneumococcal diseases, and how this 
relationship might be affected by an individual’s gender and age. The Chi-Square and 
Logistic Regression analysis conducted in the current study indicated that there was a 
significant relationship between vaccination with PCV13 and the reduction in incident 
cases for invasive pneumococcal diseases influenced by province type; however the 
relationship was not influenced by age group and gender. Table 15 provides a summary 
of the results for all analyses. There were no statistically significant relationships between 
any of the predictor variables, concluding that the predictor variables and the interaction 
effects do not have a significant effect on the outcome variable. 
 In Chapter 5, I cover a detailed discussion of these results as well as presented the 
















Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
The purpose of this study was to determine whether there was an association 
between the introduction of PCV13 and new cases of pneumococcal disease in two 
provinces in central Africa and how this relationship might be influenced by an 
individual’s gender and/or age. The findings of this study contribute to the existing body 
of literature (Chibuk, Robinson, & Hartfield, 2010; Ercan, Severge, Topkaya, Ercan, & 
Altınkaya, 2011; Poehling et al., 2006; Whitney et al., 2003) on the implications of 
vaccination with PCV13 in relation to invasive pneumococcal diseases by confirming or 
not the relationship with the reduction of the disease and by determining that most of the 
circulating serotypes in the African country are not covered by the PCV13 vaccine. Prior 
to the current study, no scholar has explored the association between vaccination with 
PCV13 and the reduction in invasive disease in the DRC. This research study filled that 
gap by offering a new perspective on the impact of the PCV13 vaccine to the field of 
public health. The study’s sample consisted of children 5-years-old or less who live in the 
DRC and have visited the sentinel surveillance sites complaining of signs and symptoms 
corresponding with the case definition of pneumococcal disease during the years 2009-
2013. The three research questions for this study integrated a chi-square analysis and two 
logistic regression analyses to determine the effect of vaccination of PCV13 on the 
reduction of invasive pneumococcal diseases and to determine if that effect is dependent 
on gender and age. This study was conducted to explore whether there was a relationship 





pneumococcal diseases and how this might be affected by a child’s gender or age. The 
design of this study was a quantitative, quasi-experimental research design. Data were 
derived from DRC’s archival surveillance data for pneumococcal diseases collected from 
the established three sentinel surveillance sites. 
Interpretation of Findings 
In this study, a sample of 380 children located within the DRC was evaluated. 
Data were entered into SPSS 21.0 and were then tested using chi-square and logistic 
regression analysis to evaluate the research questions.  
Results of Research Hypothesis 1 
Using SPSS 21.0, Hypothesis 1 was evaluated using a chi-square to determine if 
there was a difference between incident cases in Kinshasa province following the 
introduction of PCV13 and the Katanga province where the vaccine was not introduced. 
 Results from Analyses 1 indicated that a significant difference existed in the 
number of incident cases of invasive pneumococcal diseases between the Kinshasa 
province following the introduction of PCV 13 vaccine and a comparison group in the 
Katanga province where the vaccine was not introduced (χ²= 12.302; p <0.001). Because 
P value = 0.000 < 0.05, I rejected the null hypothesis. The number of incident cases of 
invasive pneumococcal disease is significantly higher among children in the province of 
Katanga where the PCV 13 vaccine was not introduced. Because the PCV13 vaccination 
coverage was higher than 80% in the Kinshasa province for the years 2012 and 2013, it is 







Results of Research Hypothesis 2 
Using SPSS 21.0, Hypothesis 2 was evaluated using logistic regression to 
determine if a significant relationship existed between age and incident cases of invasive 
pneumococcal disease in children among the Kinshasa province following the 
introduction of PCV13 and Katanga province where the vaccine was not introduced.   
 Results from Analyses 2 indicated that no significant relationship existed between 
age and incident cases of invasive pneumococcal disease in children among the Kinshasa 
province following the introduction of PCV13 and Katanga province where the vaccine 
was not introduced (aOR 0.574, 95% CI 1.186-0.278, P= .134), but that there was a 
difference in incident cases of invasive pneumococcal diseases between the Kinshasa 
province and the Katanga province (χ²= 13.207, p < .01 with df = 2) confirmed by (aOR 
0.372, 95% CI 0.709-0.195, P=0.003).  
Results of Research Hypothesis 3 
Using SPSS 21.0, Hypothesis 3 was evaluated using logistic regression to 
determine if a significant relationship existed between gender and incident cases of 
invasive pneumococcal disease in children among the Kinshasa province following the 
introduction of PCV13 and Katanga province where the vaccine was not introduced.  
 Results from Analyses 3 indicated that no significant difference existed between 
gender and incident cases of invasive pneumococcal disease in children among the 
Kinshasa province following the introduction of PCV13 and Katanga province where the 
vaccine was not introduced (aOR 1.047, 95% CI 1.929-0.569, P= 0.882). Because P 
value = 0.882 > 0.05, I accepted the null hypothesis. At α=0.05 level of significance there 





and females in the number of incident cases of invasive pneumococcal diseases in 
children between the Kinshasa province following the introduction of PCV 13 vaccine 
and the Katanga province where the vaccine was not introduced.    
These results represent new findings in the DRC that contribute to the literature. 
Whitney et al. (2003) provided evidence that the pneumococcal conjugate vaccine seven 
valent (PCV7) induced a decline in the invasive disease in children, especially the less 
than 2 years of age, and may also reduce the burden of disease in adults. Poehling et al. 
(2006) observed a significant decrease of at least 60% in children less than 2 years of age 
after vaccination with PCV 7. Researchers have not been able to determine whether the 
association between the reduction in invasive disease after vaccination with the 
pneumococcal conjugate vaccine and gender exist. This may further lead the DRC’s six 
remaining provinces and other African countries to introduce the vaccine. Additionally 
the findings have the potential to assist public health practitioners in promoting 
prevention of the invasive diseases by adopting childhood vaccination with the PCV13 
vaccine. Evidence of the relationship between PCV13 and reduction in the incidence of 
invasive pneumococcal diseases was found for children 5 years of age or under, also an 
age where the disease is more frequent in DRC. This assisted with distinguishing the age 
group at risk of the disease and will help determine actions directed toward these 
particular children. The results in this study support prior research findings that had also 
affirmed the impact of pneumococcal conjugate vaccines on the reduction of the invasive 





Strengths of the Study 
In this study, I identified the age group most at risk for invasive pneumococcal 
diseases in the DRC, necessary to better direct interventions. The data obtained from the 
DRC government consisted of archival surveillance and vaccination data collected as part 
of the national surveillance system. The sample consisted of children 5 years of age and 
under who have visited a sentinel surveillance site complaining of symptoms of 
pneumococcal disease during the years 2009-2013. The data set files were in Excel and 
Access format, which were later imported into SPSS for analysis. For proper analysis, the 
data were checked for missing values and tested for normality. 
Analytic guidelines were followed to conduct a power analysis in order to 
determine the minimum sample size needed. A minimum of 88 participants was required 
to produce an 80% probability of rejecting the null hypothesis (Faul et al., 2007). Further, 
all data collected are kept private and strictly confidential according to the public health 
laws requirements. 
Limitations of the Study 
The results of this study have a number of limitations that must be acknowledged 
as with most research. Despite these limitations to the study findings, the conclusions of 
the study make a contribution to the existing body of literature on this subject. First, the 
causal relationship between PCV 13 and the reduction in incidence cases of invasive 
pneumococcal diseases might not have been accurate in children based on the fact that 
only a weighted average of pneumococcal vaccination rates for children was used to 
estimate the coverage of children in Kinshasa province. The data provided did not include 





not done for all positive cases, especially in the Katanga province; therefore, all possible 
circulating serotypes are unknown to identify if they were included in the PCV13 
vaccine. Thirdly, there could be variations in pneumococcal vaccine effectiveness within 
different disease seasons; this needs to be taken into account. Finally, this was a quasi-
experimental study that provided information in a limited time frame and may not predict 
future vaccination rates.  
Generalizability 
This study targeted only children who have visited one of the three sentinel 
surveillance sites, data from other cities were not included. This may have impacted the 
generalizability of my results because I only used patients visiting three hospitals among 
many; however, it was assumed to be generalizable because the three hospitals were 
chosen for pneumococcal diseases referral sites, and the most important information was 
the lab result. The sample consisted of children who were up to 5-years-old, residing in 
the DRC and had visited the sentinel sites in 2009 – 2013.   
Validity 
This study was conducted using an archived data that were originally collected 
with a case investigation form for pneumococcal disease designed by the DRC’s ministry 
of health. The clinical and laboratory diagnostic of pneumococcal diseases were made 
based on the WHO’s algorithm provided to member countries (WHO, 2012). Data from 
the case investigation form were collected as part of the normal surveillance system for 
pneumococcal diseases in DRC. Although the WHO (2012) considered the case 
investigation form a reliable and valid tool for diagnosing pneumococcal diseases, 





timing of the data collection could have affected the way people are thinking when taking 
the survey. In addition, the condition of the sick child could have been a distraction for 
the parents.  
Reliability 
The pneumococcal diseases case investigation form is a reliable tool that is 
dependable and accurate (WHO, 2012). The DRC ministry of health is responsible for 
collecting and disseminating data necessary for planning and executing public health 
activities in the country. As a reliable source of the nationwide surveillance data for 
diseases, the DRC ministry of health facilitates through its specialized offices, 
community health planning, and monitoring prevention effectively. To generate reliable 
statistics, a minimum sample size of 88 participants was needed according to the power 
analysis. As a means to control reliability, 380 DRC national representations of those up 
to 5 years were sampled. However, the use of secondary data increases the probability of 
measurement error and data variance. Error can occur due to constructs and content 
validity of the data collected; however, standard error could have prevented errors to 
invalidate the secondary data. For instance, the case investigation questionnaire can have 
control over reliability because health care clinicians in the sentinel sites were onsite to 
assess clinical findings for pneumococcal diseases. Moreover, participants may have been 
improperly classified as not having pneumococcal diseases impacting this present study’s 
reliability. Also as a researcher, my actions and attitude when collecting the data could 
have caused some measurement errors. Finally, quality control processes such as 
checking for missing and normality testing were done before statistical analysis to verify 






Recommendations for Future Research  
          The results of this study provided a basis for a number of recommendations.  Some 
recommendations for further research are grounded in the limitations listed above. To test 
this study’s hypotheses, archival data during 2009 – 2013 was chosen from the DRC 
archival surveillance data set. The entire data set was used to reflect the entire population 
and to answer the research questions after data cleaning. To better the generalizability to 
the DRC population as a whole, a future study may consider including children who have 
visited other hospitals in the provinces of Kinshasa and Katanga as part of the larger 
group, or may examine these populations individually to gain insights into how they may 
be similar to or different from the participant who were eligible for inclusion in the study. 
            Additional recommendations for further research emerged from an examination of 
the results of this study in relation to the literature reviewed in Chapter Two. More 
research is needed to find more vaccines covering more serotypes. Further, data analysis 
involving circulating serotypes in DRC could add to the knowledge of serotypes not 
included in the vaccine. 
Recommendations for Practice 
Evidence showed that children less than five years are more at risk for invasive 
pneumococcal diseases, with an increased incidence in the less than 2 years age group 
(Knoll et al., 2009). It was also shown that the PCV13 had an impact in that age group 
and on the vaccine contained serotypes (CDC, 2012). Yet, despite the cost effectiveness 
many countries had not introduced the PCV13 in their childhood vaccination calendar. 





always affordable especially in sub Saharan Africa. Ayieko et al., (2013) in their 
Assessment of Health Benefits and Cost-Effectiveness of 10-Valent and 13-Valent 
Pneumococcal Conjugate vaccination in Kenyan Children found that by investing 
annually $14million in the vaccine, 43% of infection with the disease could be avoided; 
this could help save $1.97 million in treatment cost and a 6.1 % reduction in child 
mortality; their findings showed that introducing the pneumococcal conjugate vaccine is 
highly cost effective. The mortality caused by invasive pneumococcal diseases is high 
due in part to reasons cited above but also to antibiotic resistance observed more and 
more (Ayieko et al., 2013). Therefore it is recommended that vaccination with 
Pneumococcal conjugates vaccines are put in priority in actions for reducing the 
morbidity and mortality caused by invasive pneumococcal diseases in countries. In 
addition, entire communities in the Kinshasa province could have been protected since 
the vaccination coverage assessed from the immunization data provided by the DRC’s 
Ministry of health was at a good level to induce heard immunity. 
Implications for Positive Social Change 
          It is expected that the conclusions of this study will translate into significantly 
impacting the way invasive pneumococcal disease, which leads to loss of life or poor 
quality of live is handled in the DRC. In 2009 the pneumococcal disease incidence was ≥ 
3000 per 100,000 children less than 5-years of age in DRC; the mortality rate was 
between 300 and 500 per 100,000 children less than 5-years of age (Wang, 2009). 
Further, the results can be applied to the remaining provinces where the PCV13 vaccine 
was not introduced as well as the African countries who have not yet adopted the 





measure of preventing a deadly disease will contribute to improving the health of 
children in DRC in particular and of the entire world in general. This study focused on 
exploring whether there was a relationship between vaccination with PCV13 and the 
reduction of invasive pneumococcal diseases, and how this relationship was affected by 
an individual’s gender and age. Understanding the connection between PCV13 
vaccination and the reduction of the disease provided a basis on which to foster positive 
social change in DRC and Africa in general. 
          Also, the results of this study supported positive social change by broadening the 
understanding of a relationship between PCV13 and the reduction in incidence of 
invasive pneumococcal diseases in a place like DRC. This increased knowledge will 
positively enhance the general public’s understanding of not only the burden of the 
diseases on children up to 5-years of age but also the way to prevent them effectively. 
Surveillance data in DRC showed circulation of non-vaccine serotypes 2, 7C, 13, 15B, 
22F, 23A and 33F. The presence of circulating non vaccine serotypes in DRC suggested 
that there is a need for further research for a vaccine including more serotypes likely to 
continue decreasing the burden of invasive disease in children. 
Conclusion 
        The consequences of invasive pneumococcal diseases are significant and evidenced 
by their yearly high mortality. This constitutes a public health problem that needs to be 
addressed. Pneumococcal disease can lead to severe health problems, including 
pneumonia, blood infections, and meningitis that can impair an individual’s quality of life 
and cause death. Further, existing research indicates that there is a high incidence of 





antibiotics resistance has prompted the recommendation to place attention on prevention 
of the diseases; and the most cost effective prevention of pneumococcal disease in 
children is through vaccination with pneumococcal conjugate vaccine (Bergman et al., 
2008). The most serotypes containing vaccine available to date is the pneumococcal 
conjugate vaccine thirteen valent (PCV13) containing 13 of the most disease causing 
streptococcus pneumoniae serotypes. By adopting the vaccine in the child’s vaccination 
calendar, public health policy makers and healthcare practitioners can enable positive 
outcomes and enhance children quality of life in a cost-effective manner. 
         The results of this study provided strong evidence for decision-making that will 
change the lives of children residing in the DRC, who are up to 5-years of age by 
implementing practices that acknowledge and address the burden of pneumococcal 
diseases. This study reported ample statistical evidence to suggest an important role for 
PCV13 in the reduction of incidence of above cited diseases. However gender and age 
were found to have no significant impact on the relationship between PCV13 and the 
reduction of the disease incidence. A child that is completely vaccinated acquires 
immunity against vaccine preventable diseases (CDC, 2013); According to Esposito and 
Principi (2015), vaccination with PCV 13 can protect an entire community through heard 
immunity. The results of this study could suggest that more people where protected 
through heard immunity because the vaccination coverage with PCV13 in the Kinshasa 
province was over 80% for the years 2012-2013. Further, this study supported positive 
social change by broadening the understanding of a relationship between PCV13 and the 
reduction in incidence of invasive pneumococcal diseases in a place like DRC and 
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Appendix B: Authorization from the Ministry of Health of DRC 
 
Dr Aissata Coulibaly Diaha 










For my PhD in Epidemiology I chose to study the impact of vaccination with PCV 13 on 
the reduction of incident cases of diseases due to streptococcus pneumonia. To that effect 
I would like to obtain from the Ministry of Health the authorization to use the following 
data: 
- Available data from the sentinel surveillance sites of Kalembelembe and 
Kingasani in the Kinshasa province and of Sendwe in the Katanga province for 
the years 2009 through 2013. 
- Surveillance and vaccination data for the districts of Kalembelembe and 
Kingasani before and after the introduction of the vaccine and for 
Lubumbashi/district of Sendwe where the vaccine was not introduced for the 
years 2009-2013. 
- Serotype data from the regional reference laboratory for the years 2009-2013. 
 
Hoping to get a favorable answer, please accept my best regards. 
 
                          Aissata Coulibaly 
   _________________________________________      
















Appendix C: Case Investigation Form 
 
INFECTIONS BACTERIENNES INVASIVES – FORMULAIRE D’INVESTIGATION DE CAS SUSPECT 
Nom du patient:                                               Date d’admission ____ /____ /______  No. ID du cas: _____________ 
Numero du dossier, si disponible ________________________ Nom de l’hôpital:  ___________________________  
PARTIE 1: INFORMATION GENERALE 
Sexe:  Masculin   Féminin             Age        M       J           Date de naissance       J     M    A 
Nom de père/de la mère: __________________________________________________ 
ZS de Résidence: ___________________________ Province/Région: __________________________           
Ville/village:____________________________________ Village/Quartier: __________________________ 
Adresse : _________________________ Numéro de téléphone mobile:_______________ 
 
PARTIE 2: INFORMATION CLINIQUE 
Date de début de la maladie: ______/_____/______ 
Enfant hospitalisé? _____ (oui/non/pas connu)       Date d’admission: ______/_____/______ 
Diagnostic à l’admission #1_____________________ Diagnostic à l’admission #2 ____________________ 
Autres infections co-morbides :…………………………………………………………….. 
Antibiotiques avant l’admission? _____ (oui/non/pas connu)          
Le cas a-t-il eu des signes et symptômes suivants? (cochez tous s’appliquant) 
Des convulsions         Incapable de s’alimenter          Antécédent de fièvre                      Stridor   
Altération de la conscience        Respiration rapide  Déshydratation                      Toux 
Difficulté de respiration  Tirage sous costal  Nuque raide   
Fontanelle bombée      Inconnu   Autre: ________________ 
Cas répondant à la définition de cas suspect de méningite : Oui/ Non 
LCR prélevé? ___ (oui/non) Si oui, date et l’heure du prélèvement: _____/_____/_____ (______:_____) 
Aspect de LCR au prélèvement:……………………………Pression : goutte à goutte         hyperbare 







PART 3: STATUT VACCINAL 
Vaccination de routine?         O         N      I                                    Vaccination pendant une campagne? 
                                                           Nbre 
Vaccin Hib?                -----  ------   -----   ----     Vaccin Hib?                        O      N      I        O: Oui     
 Vaccin Pneumo?                 -----  ------   -----   ----                   Vaccin Pneumo?                O      N      I         N: Non   
 Vaccin Meningococcique   -----  ------   -----   ----                   Vaccin Meningococcique   O      N      I        I: Inconnu 
Dates des doses de Routine Hib:     Dose #1___/____/___ Dose #2 ____/___/____ Dose #3 ____/____/____ 
Dates des doses de  Routine Pneumo: Dose #1___/____/___ Dose #2 ____/___/____ Dose #3 ____/____/____ 
Dates des  doses Routine Meningococcal: Dose #1__/___/___ Dose #2 ____/___/____ Dose #3 ___/____/____ 
Source d’information?  Carte de vaccination   Histoire orale         registre   Inconnue 
Commentaire : 
Nom du patient:                                               Date d’admission ____ /____ /______  No. ID du cas: _____________ 
Numero du dossier, si disponible ________________________Nom de l’hôpital:  ___________________________  
PARTIE 4: RESULTAT A LA SORTIE 
Résultat a la sorite:  Guéri        Date de sortie (ou transfert or décès): ____/____/_____  
(veuillez cocher (  √  )   Décès    Sorti contre l’avis médical 
Transfert  inconnu   
Des séquelles à la sortie?    Si oui, veuillez décrire: _________________________________ 
Classification finale à la sortie?  
Pneumonie       Méningite               Septicémie  Autres                   Inconnu 
Si autres, spécifier : ___________________    
 
PART 5: RESULTATS DU LABORATOIRE 
No d’identification de l’échantillon : ________________ 
Date de réception du LCR au labo:  ____/____/____ L’heure de réception: (______:_____ ) 
Apparence du LCR: (cochez un)  Echantillon de LCR traité? 1-Oui     2-Non     
1 - Claire       Si non, raison de non-traitement?____________________________  






2 - Trouble          
3 – Xanthos.        Résultat du LCR enregistré? 1-Oui     2-Non     
4 – Purulent        Résultat de Gram:  Cocci G+     Cocci G-       Coccobacille G-       
5 – Autres                       Indéterminé       
6 – Hémon.       LCR Protéine:  ________ (cochez un) ≤100        >100      
9 – Inconnu       LCR Glucose:   ________ (cochez un)   <40     40-100     >100      
Autres spécifiez :  _______________________ 
Résultat culture de LCR            Latex traité? 1-Oui     2-Non    PCR fait? 1-Oui     2-Non      
1-H. influenzae   1-Hib            1-H. influenzae      
2-S. pneumoniae   2-S. pneumoniae   2-S. pneumoniae      
3-N. meningitidis           3-N. meningitidis          3-N. meningitidis      
4- Autre organisme                   4-N. mening W135    4-Négatif       
5-Stérile    5-Négatif 
6-Culture non faite    6-Autre non spec.    Autre test fait  
Autre, spécifiez : ___________________     1-Binax                                                                                                                                              
2-Identification biochimie        
Num leucocytes: _______ (cochez un)   <10     10-100     >100      3-Optochine                              
                                           Non fait        4- facteurs X et V                      
                                                                                                                                5-Autre                                   
                                                                                        6-Pas d’autre test      
                   Si autre, résultat :  ______________ 
 
PART 6: LABORATOIRE DE REFERENCE REGIONAL 
L’isolé a-t-il été envoyé au LRR? ____(oui/non)   Si oui, date d’envoi:  _____/_____/_____  
NOTES: __________________________________________________________________________________ 
INFECTIONS BACTERIENNES INVASIVES – LABORATOIRE DE REFERENCE REGIONAL  
Nom du patient:                                              Date d’admission ____ /____ /______  No. ID du cas: ________ 
Numero du dossier, si disponible ____________________Nom de l’hôpital:  ___________________________  
LCR             No d’identification de l’échantillon : ________________ 





                                                                                                                Comment était conservé?  
Date d’envoi du résultat     1-(Congélateur -20ºC)        
du LCR au pavillon:   ____/____/____                  2-(Congélateur -70ºC)                 
Pathogène isolé du LCR  1- S. pneumoniae     2- N. meningitidis     3-Hib     4- Autre organisme      
Si autre, spécifiez : ________________________________ 
Autre fluide stérile 
Autre liquide stérile prélevé (autre que le sang et le LCR) 1-Oui     2-Non    Quel ? __________________ 
Résultat de la culture d’autre liquide stérile prélevé : _______________________________________________ 
Isolat 
Isolat envoyé au LRR? 1-Oui     2-Non      
Date d’envoie de l’isolat au LRR:   _____/_____/_____  Date de réception par le LRR:  
_____/_____/_____ 
Date d’envoi du résultat au labo national:  _____/_____/_____ Date de réception:  _____/_____/_____ 
Commentaire du labo national : ___________________________________________________________ 
 
RÉSULTATS DU TEST DE SENSIBILITÉ ANTIMICROBIENNE 
H. influenzae Serotype identifié 1-a      2-b      3-c      4-d      5-e      6-f      7-non typé       
Test fait? 1-Oui     2-Non     (cochez 1-Sensible    2-Résistant   3-Intermediare) 
Oxacilline (1mg)          Chloramphenicol (30mg)       Cefotaxime (30mg)           
Pénicilline (10U)       Cotrimoxazole (25mg)         Ciprofloxacine (5mg)       








S. pneumoniae  Serotype identifié ________ 
Test fait? 1-Oui      2-Non     (cochez 1-Sensible    2-Résistant   3-Intermediare) 
Oxacilline (1mg)          Chloramphenicol (30mg)       Cefotaxime (30mg)            
Pénicilline (10U)       Cotrimoxazole (25mg)         Ciprofloxacine (5mg)          
Ampicilline (10U)       Erythromycin (15mg)                          Autres :______________ 
N. mengitidis Serogroup identifié 1-A      2-C      3-Y      4-W135      5-autre       
Test fait? 1-Oui     2-Non     (cochez 1-Sensible    2-Résistant   3-Intermediare) 
Oxacilline (1mg)          Chloramphenicol (30mg)       Cefotaxime (30mg)              
Pénicilline (10U)       Cotrimoxazole (25mg)         Ciprofloxacine (5mg)          
Ampicilline (10U)       Erythromycin (15mg)       Autres : _________ 
 
 
